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Background: Modifiable risk factors for prostate cancer, and specifically lethal prostate cancer, 
are needed. Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) may protect 
against prostate cancer development and progression, but the current evidence base is limited. 
To elucidate the potential role of NSAIDs in the primary and tertiary prevention of lethal prostate 
cancer, this dissertation investigated associations between NSAID use and (1) prostate cancer 
incidence, including incidence of lethal disease, and mortality, (2) prostate cancer outcomes 
among men diagnosed with prostate cancer, and (3) inflammation and markers of specific 
immune cells in benign prostate tissue. 
Methods: Associations between NSAID use and prostate cancer incidence and mortality were 
estimated for men in the Atherosclerosis Risk in Communities (ARIC) study, which enrolled 
participants from four communities in1987-1989. Associations between NSAID use and case-
fatality were studied among men diagnosed with prostate cancer during ARIC follow-up (1987-
2012), and associations between NSAID use and prostate cancer recurrence were studied 
among men treated surgically for localized prostate cancer at the Johns Hopkins Hospital (JHH) 
between 1993-2006. Associations between aspirin use and the presence and extent of 
inflammation, as well as markers of specific immune cells, were examined in benign prostate 
tissue collected without indication from a subset of men from the placebo arm of the Prostate 
Cancer Prevention Trial (PCPT), who were enrolled in 1993-1997. 
Results: In the ARIC study, aspirin but not non-aspirin NSAID use was inversely associated with 
lethal and fatal prostate cancer. Aspirin use prior to diagnosis was also associated with prostate 
cancer case-fatality. In the JHH study, neither aspirin nor non-aspirin NSAID use pre- or post-
surgery were inversely associated with prostate cancer recurrence. For aspirin, there was 
suggestive evidence of a positive association. In the PCPT study, aspirin use at trial entry was 
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inversely associated with the extent of inflammation and the abundance of FoxP3, a marker of T 
regulatory cells, in benign prostate tissue collected seven years later. 
Conclusions: This dissertation provides support for the role of aspirin in the primary prevention 
of lethal prostate cancer, and suggests that aspirin may act by reducing the extent of 
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Prostate cancer is one of the leading causes of cancer incidence and mortality in the 
U.S. and worldwide. In the U.S., approximately 164,690 new cases and 29,430 deaths from 
prostate cancer are expected to occur in 2018, representing 19% and 9% of all new cases and 
deaths among men, respectively (1). Globally, prostate cancer accounts for approximately 15% 
of incident cancers and 7% of cancer deaths among men (2). Prostate cancer deaths result in 
hundreds of thousands of years of potential life lost (YPLL) in the U.S. per year; there were an 
estimated 378,069 YPLL due to prostate cancer in 2010, and this number is projected to rise to 
951,753 by 2050 (3). 
The mortality rate from prostate cancer has declined over the past 20 years (1), likely 
due to the advent of prostate-specific antigen (PSA) screening, improved early detection and 
early treatment, and improved treatment of advanced prostate cancer (4). Early detection and 
treatment cannot curb all deaths from prostate cancer, however, as some prostate cancers 
progress despite early intervention. Moreover, PSA screening has led to vast overdiagnosis and 
overtreatment of prostate cancers unlikely to cause harm, with 20-50% of screen-detected 
prostate cancers currently thought to be overdiagnosed (5). Overdiagnosis and overtreatment of 
prostate cancer result in unnecessary healthcare costs and subject patients to undue physical 
and psychological harms. To circumvent problems related to overdiagnosis and overtreatment, 
and to further reduce morbidity and mortality due to prostate cancer, increased focus on 
prostate cancer prevention is needed.  
 
Current challenges to prostate cancer prevention 
Unfortunately, prevention of prostate cancer has proven difficult. This is in part due to 
the fact that the strongest risk factors for prostate cancer incidence and mortality – increasing 
age, African-American ancestry, and family history of prostate cancer – are all non-modifiable 
3 
 
(1). There is general consensus that cigarette smoking is associated with prostate cancer 
mortality and case-fatality (6) and obesity is associated with advanced and fatal prostate cancer 
(7), but there are otherwise no modifiable risk factors definitively linked to prostate cancer.  
The complex etiology and heterogeneity of prostate cancer has also likely hindered 
efforts to identify risk factors to target for prevention. Prostate cancer outcomes vary widely; 
most prostate cancers follow an indolent disease course and are unlikely to cause harm during 
a man’s lifetime, while others progress rapidly and become lethal (8). Indolent and lethal 
prostate tumors appear to have distinct etiologies with differing sets of risk factors (9, 10), and 
ideally would be studied as distinct prostate cancer subtypes. However, there is currently no 
ideal method for distinguishing between indolent and lethal tumors at the time of prostate cancer 
diagnosis. Stage, grade, and diagnostic PSA value are widely used as prognostic indicators 
(11), but these variables are imperfect predictors of lethal potential (10), particularly in the 
presence of PSA screening and the resultant lead-time bias. Due to the difficulty of 
distinguishing indolent from lethal prostate cancers, as well as the low incidence of lethal 
prostate cancer, most epidemiologic studies have historically examined these cancers in 
combination, despite the fact that this approach may obscure true associations with lethal 
disease. 
The high prevalence of indolent prostate cancer has also rendered studies subject to 
detection bias, or bias arising from the association between potential risk factors and the 
likelihood of undergoing diagnostic procedures (12). The vast majority of prostate cancers are 
asymptomatic and detected incidentally via screening (13). As a result, it is difficult to discern 
whether certain factors are associated with risk of developing prostate cancer, or with the 
propensity to undergo prostate cancer screening and/or biopsy and have prostate cancer 
detected. Several cancer risk factors have been associated with the likelihood of undergoing 
prostate biopsy, including age, positive family history, body mass index, smoking status, and 
use of common medications (14). Detection bias in studies of prostate cancer risk factors is thus 
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likely, and failure to account for differential opportunities for detection may lead to inferences 
that are quantitatively or qualitatively biased (15). Because lethal prostate cancer is rare and 
more likely to become symptomatic and detected regardless of screening, studies using lethal 
prostate cancer as an endpoint may be less influenced by detection bias. Prostate cancer 
prevention research should arguably focus on lethal prostate cancer moving forward, both to 
limit the impact of detection bias, and to identify risk factors for the subset of prostate cancers 
that cause the greatest morbidity and mortality. 
 
 
NSAIDs as promising cancer preventive agents 
One potential modifiable risk factor for lethal prostate cancer is regular use of aspirin or 
other nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs are a class of drugs widely used 
to treat pain, inflammation, and fever. Aspirin is also indicated for primary and secondary 
prevention of cardiovascular disease (CVD). While the cardioprotective benefits of aspirin are 
well-established, potential benefits of aspirin and non-aspirin NSAIDs (NA-NSAIDs) for other 
chronic diseases such as cancer are not yet fully understood.  
 
Mechanisms of action of NSAIDs 
NSAIDs primarily act by inhibiting the cyclooxygenase enzymes (COX-1, COX-2), 
thereby inhibiting the conversion of arachidonic acid into prostanoids (prostaglandins, 
prostacyclin, thromboxane A2, Figure 1-1). COX-1 is constitutively expressed in most cells and 
synthesizes prostanoids for housekeeping functions, such as gastrointestinal mucosal defense, 
platelet aggregation, renal homeostasis, and parturition (16). COX-2, on the other hand, is 
induced in the presence of inflammation and synthesizes prostanoids that serve as 
inflammatory mediators (16, 17).  
5 
 
Most NSAIDs, including aspirin, are non-selective COX inhibitors, meaning that they 
inhibit both COX-1 and COX-2 enzymes. Inhibition of COX-2 leads to the anti-inflammatory 
property of NSAIDs, but simultaneous inhibition of COX-1 can disrupt homeostatic processes, 
leading to adverse events such as bleeding and ulcers (16). In an attempt to preserve the anti-
inflammatory effects of NSAIDs resulting from COX-2 inhibition while avoiding the risk of 
gastrointestinal toxicities resulting from COX-1 inhibition, selective COX-2 inhibitors (coxibs) 
were developed and marketed. However, these drugs were found to significantly increase risk of 
adverse cardiovascular events, and all but one were withdrawn from the U.S. market in the early 
2000s. 
Aspirin is unique from other NSAIDs in that it acetylates and irreversibly inhibits the 
COX-1 and COX-2 enzymes. Unlike other NSAIDs, aspirin also preferentially inhibits COX-1 
over COX-2 when taken at low doses (18). For this reason, aspirin is more effective than non-
aspirin NSAIDs (NA-NSAIDs) as an antiplatelet agent. Aspirin’s inactivation of COX-1 in 
platelets leads to decreased production of thromboxane A2, a promoter of platelet aggregation 
and vasoconstriction, and because platelets lack nuclei and cannot regenerate COX-1, the 
effects of aspirin persist for the duration of the platelet lifespan. Low doses of aspirin (75-100 
mg per day) are sufficient to bring about these antithrombotic effects, while higher doses of 
aspirin (≥300 mg per day) are needed for aspirin to inhibit COX-2 and reduce inflammation (18). 
 
Mechanisms of action against cancer 
Aspirin and NA-NSAIDs are hypothesized to protect against cancer via both COX-
dependent and COX-independent mechanisms. COX-dependent mechanisms include inhibition 
of COX-2, which is overexpressed in prostate cancer tissue (19), as well as in tissue from 
several other cancer types (20-24). Increased expression of COX-2 in diagnostic tumor tissue is 
also positively associated with risk of biochemical recurrence and metastases in men treated for 
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prostate cancer (25). Decreased COX-2 expression may hinder cancer development and 
progression by blocking synthesis of the pro-inflammatory prostaglandin E2 (PGE2), which 
inhibits apoptosis, stimulates cell proliferation, migration, and invasion, and suppresses immune 
responses (26, 27). In general, chronic inflammation is a well-accepted enabling characteristic 
of cancer (28) and has been implicated in prostate cancer specifically (29); it thus seems 
plausible that the anti-inflammatory properties of NSAIDs could lead to antineoplastic effects as 
well. 
NSAIDs may also reduce risk of cancer metastases via inhibition of COX-1 in platelets. 
Activated platelets are thought to facilitate cancer metastases through the bloodstream by 
binding to tumor cells in circulation and shielding them from immune detection (30, 31). Platelets 
also release mediators and growth factors that may promote tumor cell extravasation, 
proliferation, and angiogenesis at new, distant sites (30, 31). By impeding platelet function, 
NSAIDs and aspirin in particular may disrupt these tumor cell-platelet interactions and 
encumber cancer spread. 
COX-independent mechanisms linking NSAIDs to cancer incidence and progression are 
not well understood, but may involve AMPK and mTOR signaling, NF-kB signaling, ERK 
signaling, the Wnt/beta-Catein pathway, inhibition of AP-1, and/or acetylation of non-COX 
proteins (16, 32). 
 
Review of the current epidemiologic literature 
Randomized controlled trials of aspirin and cancer 
Aspirin has shown promise as an effective anti-cancer agent according to secondary 
analyses of randomized controlled trials (RCTs) of aspirin and cardiovascular outcomes. A 
meta-analysis of six RCTs of daily low-dose aspirin for primary prevention of vascular disease 
found that daily aspirin reduced overall cancer risk (hazard ratio (HR): 0.88, 95% confidence 
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interval (CI): 0.80-0.98), with the benefit increasing with increasing duration follow-up (33). In a 
meta-analysis of 34 RCTs of daily low- or high-dose aspirin for primary or secondary CVD 
prevention, allocation to daily aspirin was also observed to reduce total cancer deaths, 
particularly after five years or more of follow-up (after 5 years, odds ratio (OR): 0.63, 95% CI: 
0.49-0.82) (33). Furthermore, in a meta-analysis of five of these RCTs from the United Kingdom, 
where cancer registration and death certification procedures were well-validated and reliable, 
daily aspirin was found to reduce risk of cancer with distant metastasis (HR: 0.64, 95% CI: 0.48-
0.84), including metastasis at diagnosis and at subsequent follow-up (34). However, these 
meta-analyses excluded results from two U.S. trials examining alternate-day, low-dose aspirin 
for CVD and cancer prevention, both of which reported null findings for total cancer mortality 
(35, 36).  
From these studies, it is also difficult to discern whether results are driven by reductions 
in colorectal cancer incidence and mortality, or whether incidence and mortality from prostate 
and other cancer types are also reduced. Prostate cancer mortality was examined in a pooled 
analysis of six primary and secondary CVD prevention trials for which there were individual 
patient data available; in this analysis, allocation to daily aspirin was associated with a non-
significant reduction in prostate cancer mortality during the trial treatment period (after ≥5 years 
of follow-up, HR: 0.52, 95% CI: 0.20-1.34) (37). However, only 37 prostate cancer deaths were 
observed during the treatment period of these trials. In three of these trials with extended follow-
up of participants and 210 prostate cancer deaths, allocation to daily aspirin for at least five 
years was possibly associated with prostate cancer mortality (across 20 years of follow-up, HR: 
0.81, 95% CI: 0.61-1.06); this result was not statistically significant, but a moderate effect of 
aspirin on prostate cancer mortality could not be ruled out (37). After consideration of all 
available RCTs, the U.S. Preventive Services Task Force (USPSTF) concluded in 2016 that 
there was enough evidence to recommend aspirin for the joint primary prevention of colorectal 
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cancer and CVD, but that the evidence supporting an overall cancer mortality benefit and 
benefit for other cancer types, including prostate cancer, was inconclusive (38, 39). 
 
Observational studies of NSAIDs and prostate cancer incidence 
Several observational studies have examined regular aspirin use in relation to prostate 
cancer incidence and mortality. Algra et al. found that observational studies of aspirin and 
cancer can produce estimates similar to those from RCTs, so long as there is “an adequate 
definition of aspirin exposure, updated assessment of exposure during the follow-up period, and 
appropriate adjustment for imbalances in baseline characteristics” (40).  
Observational studies that meet these criteria have found regular aspirin use to be 
associated with an approximately 10-20% reduced risk of total incident prostate cancer (41, 42). 
Aspirin use has also been associated with an approximately 20% reduced risk of advanced 
prostate cancer, with advanced disease most often defined by cancer stage and/or grade at 
diagnosis (41, 42). The pooled estimates for total prostate cancer have shown evidence of 
heterogeneity (p-heterogeneity=0.05) and appear to vary by study characteristics such as 
geographic location, source of medications data, and methods for accounting for detection bias; 
in contrast, pooled estimates for advanced prostate cancer have been relatively consistent (p-
heterogeneity=0.66) (42). NA-NSAID use has been associated with a 0-10% reduced risk of 
total incident prostate cancer and does not appear associated with advanced prostate cancer, 
though there has been significant heterogeneity across study (41, 42). Few studies have 
investigated the relationship between aspirin use and lethal prostate cancer specifically (Table 
1-1). In the Health Professionals Follow-up Study (HPFS), current use of aspirin at least two 
times per week was non-significantly associated with a reduced risk of lethal prostate cancer, 
defined as prostate cancer that was metastatic at diagnosis or that metastasized or caused 
death during follow-up (HR: 0.84, 95% CI: 0.69-1.02) (43). Former aspirin use was also possibly 
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inversely associated with lethal prostate cancer (HR: 0.86, 95% CI: 0.67-1.11). A significant 
dose-response was observed for increasing number of tablets per week (p-trend=0.04), but not 
for increasing days per week of use or cumulative duration of use.  Similarly, in the Physicians’ 
Health Study (PHS), in which aspirin use was initially randomized (1981/2-1988) and then 
offered to study participants after trial completion, aspirin use at least three days per week for 
one year or longer was significantly associated with lethal prostate cancer, both for current use 
(HR: 0.68, 95% CI: 0.52-0.89) and former use (HR: 0.54, 95% CI: 0.40-0.74) (44). The inverse 
association with current aspirin use was consistent regardless of duration of use, and the 
association with former use was consistent regardless of time since stopping. Interestingly, 
associations for current and former use were only observed for cases diagnosed before the 
PSA era; associations in the PSA era were null. A more recent analysis in HPFS reported no 
association between aspirin use at least twice per week and prostate cancer that was metastatic 
or regionally advanced at diagnosis (T3b, N1, or M1) or that metastasized or caused death 
during follow-up (HR: 0.97, 95% CI: 0.85-1.10) (45). This discordance across HPFS analyses 
could be due to the inclusion of T3b cancers in the definition of lethal prostate cancer (in the 
second analysis), or to the differing study periods (1988-2006 for the first analysis, 1986-2012 
for the second analysis, which overlaps more with the PSA era). In both of these studies of 
aspirin and lethal prostate cancer, very few non-white study participants were included (Table 
1-1). To our knowledge, the association between NA-NSAID use and lethal prostate cancer has 
not yet been studied. 
 
Observational studies of NSAIDs and prostate cancer survival 
Several studies have also examined aspirin and NA-NSAID use and prostate cancer 
outcomes following diagnosis. Specifically, studies have examined both pre-diagnostic aspirin 
use (46-50) and post-diagnostic aspirin use (46, 48-53) in relation to prostate cancer case-
fatality, but results have been largely inconsistent, with results ranging from protective to null to 
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harmful (Table 1-2). Results for NA-NSAID use have been similarly conflicting (49, 50, 53). 
These inconsistencies could be due to differences in the way NSAID use was measured and 
operationalized; studies assessed NSAID use at varying time intervals before and after 
diagnosis, defined “regular” use in different ways, and used various sources of medications 
data, including self-report and prescription medication databases. Differences between the 
studies could also be driven by differences in study populations, in outcome ascertainment 
methods, or in the prevalence or ability to adjust for confounders. As with the studies of aspirin 
use and lethal prostate cancer, most studies of NSAID use and prostate cancer outcomes have 
been conducted in primarily white study populations, with the exception of two small studies 
(Table 1-2).  
 
NSAID use, inflammation, and immune cell profiling in the prostate 
Despite the multitude of observational studies on NSAID use and prostate cancer 
incidence and survival, little is known about the biological effects of NSAIDs on prostate tissue. 
It is hypothesized that NSAIDs reduce chronic inflammation in the prostate, and that chronic 
inflammation could therefore mediate relationships between NSAID use and prostate cancer 
risk and progression, but the association between NSAID use and intraprostatic inflammation 
has not been studied directly. Associations between aspirin use and serum C-reactive protein, 
serum pro-inflammatory cytokines, or other circulating markers of inflammation have been 
examined in randomized (54-59) and non-randomized studies (60-64), with mostly null results. 
However, it is unknown if serum markers of inflammation are correlated with inflammation in 
prostate tissue. 
One of the major barriers to this work arises from the challenge of assessing 
inflammation in normal prostate tissue. Inflammation can be studied in tissue removed for 
prostate biopsy, but biopsies are typically only done for suspicion of prostate cancer, i.e. 
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elevated PSA or abnormal digital-rectal examination. Prostate tissue may also be removed for 
treatment of benign prostatic hyperplasia and prostate cancer. However, tissue removed for 
these indications is inherently different from tissue of men without prostate conditions. Higher 
serum PSA has also been positively associated with inflammation in men without indication for 
biopsy (65). Thus, tissue removed for the indication of elevated PSA is more likely to harbor 
inflammation, and studying only tissue removed for indication can lead to biased associations 
between intraprostatic inflammation and prostate cancer risk factors or outcomes. 
If able to circumvent this challenge, epidemiologic studies could investigate associations 
between NSAID use and the presence of any inflammation, the extent of inflammation, or the 
type of inflammation (acute vs. chronic) in prostate tissue. Studies could also examine whether 
NSAID use modifies the immune cell profile within the prostate. Via COX-dependent and COX-
independent mechanisms (66), NSAID use might alter the infiltration of specific innate and 
adaptive immune cells present in the prostate (67), including: 
 Macrophages, phagocytic cells that digest microbes and cellular debris, secrete pro-
inflammatory cytokines, and present antigens to helper T cells (68). 
 Mast cells, granulocytes that release lipid mediators (such as prostaglandins) and 
cytokines (such as TNF-) that recruit macrophages to sites of inflammation, and may 
contribute to T cell-mediated chronic inflammation (68, 69). 
 Helper T cells (CD4+ T cells), which help B lymphocytes produce antibodies, 
macrophages destroy ingested microbes, and cytotoxic T cells kill infected cells (68). 
 Cytotoxic T cells (CD8+ T cells), which recognize and kill infected host cells and tumor 
cells (68). 
 Regulatory T cells (FOXP3+ T cells; Tregs), which downregulate effector T cells and 
mediate peripheral tolerance to self-antigens (68, 70). 
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The effects of NSAID use on the presence, abundance, or function of these immune cell types 
in prostate tissue collected without clinical indication is currently unknown, but could help to 
elucidate the biological mechanisms linking NSAID use to prostate cancer pathogenesis. 
 
Current knowledge gaps 
As discussed above, most studies conducted to date on NSAIDs and prostate cancer 
incidence and progression have included mostly white study participants. This is problematic 
given the documented racial disparities in prostate cancer incidence and mortality. In particular, 
black men are more likely than men of other races to develop and die from prostate cancer (71). 
Moreover, compared to white men, black men tend to have molecularly distinct prostate cancers 
(72) with differing relationships to risk factors (73-75). It is thus unclear if the current studies can 
be generalized to these men. Other limitations of the current literature include the limited 
research focusing on lethal prostate cancer specifically, the discordant results for NSAID use 
and prostate cancer case-fatality, and the lack of established biological mechanisms linking 
NSAID use to prostate cancer development and progression. As a result of these uncertainties, 
aspirin and NA-NSAID use are not currently recommended for primary or tertiary prevention of 
prostate cancer, despite accumulating evidence that they may be beneficial. 
 
Summary of the dissertation aims and potential impact 
This dissertation aims to clarify the potential role of aspirin and NA-NSAIDs in the 
prevention and control of prostate cancer, with a focus on prostate cancers that are potentially 
lethal (Figure 1-2). The first study investigates the relationship between aspirin and NA-NSAID 
use and prostate cancer incidence (total and lethal) and mortality in the Atherosclerosis Risk in 
Communities (ARIC) study. This aim augments the existing literature by examining risk of lethal 
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prostate cancer in particular, and by exploring this question in a community-based cohort that 
includes both white and black men. 
This dissertation also aims to determine whether aspirin and NA-NSAID use may be 
beneficial in improving cancer outcomes among men already diagnosed with prostate cancer. 
Specifically, this dissertation examines the relationship between aspirin and NA-NSAID use and 
prostate cancer case-fatality in the ARIC study, and prostate cancer recurrence after surgery 
among a cohort of patients treated at the Johns Hopkins Hospital. Use of these complementary 
study populations is intended to improve the generalizability of the findings, and to help shed 
light on why prior studies of NSAID use and prostate cancer outcomes have reported conflicting 
results. 
The third study examines aspirin use and the presence and extent of inflammation within 
the prostate, a possible mediator of the relationship between NSAID use and prostate cancer 
incidence and progression. This study also investigates the relationship between aspirin use 
and the abundance of specific immune cell types in benign prostate tissue. These associations 
are examined among men from the Prostate Cancer Prevention Trial, a study population that 
provides the unique opportunity to examine prostate tissue collected without clinical indication. 
To our knowledge, this study is the first to investigate whether aspirin use may actually alter the 
extent of inflammation and the immune cell profile in the prostate of men without clinical 
indication for prostate biopsy, and aims to elucidate the biological plausibility of aspirin 
influencing prostate cancer endpoints via reductions in intraprostatic inflammation.   
This research has the potential to impact public health practice by informing relevant 
guidelines, such as those released by the USPSTF. There are known risks to taking NSAIDs 
regularly; as a result, benefits must clearly outweigh potential harms for aspirin or NA-NSAID 
use to be advisable. Currently, the benefits of regular aspirin use are thought to outweigh the 
harms only for certain individuals at high risk of cardiovascular disease (i.e. individuals with a 
10% or greater 10-year risk) or colorectal cancer (i.e. individuals with Lynch syndrome) (39, 76). 
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Benefits related to prostate cancer are considered too uncertain to be factored into risk-benefit 
calculations (38, 77). However, if regular aspirin or NA-NSAID use is consistently shown to 
protect against lethal prostate cancer, either among men not yet diagnosed or among men 
already diagnosed and treated, then the benefit-to-harm ratio may be bolstered for additional 
subgroups. This could lead to the expansion of current USPSTF guidelines, to new guidelines 
for aspirin or NA-NSAID use among men already diagnosed with prostate cancer, and ultimately 




Chapter 1 Tables 
Table 1-1. Observational studies of NSAID use and lethal prostate cancer 
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Abbreviations: AA, African American; CI, confidence interval; NS, not stated; Dx, diagnosis; BCR, biochemical recurrence; BMI, body mass index; CVD, cardiovascular disease; PSA, 
prostate specific antigen; SES, socioeconomic status; NCCN, National Comprehensive Cancer Network; CCI, Charleston Comorbidity Index 
*for analyses of medications used during the year of diagnosis 




Chapter 1 Figures 
 
Figure 1-1. NSAIDs and the prostanoid synthesis pathway. Aspirin, other non-selective 
NSAIDs, and selective COX-2 inhibitors (coxibs) act by inhibiting the COX enzymes, which 
convert arachidonic acid (AA) into prostaglandin H2 (PGH2). PGH2 is then converted by 
synthases into thromboxane A2 (TXA2), prostaglandin E2 (PGE2) prostacyclin (PGI2), 
prostaglandin D2 (PGD2), and prostaglandin F2α (PGF2α), which contribute to several biological 
processes, including but not limited to those listed above. Figure from NSAIDs and Aspirin: 






Figure 1-2. Conceptual Framework. We hypothesized that regular use of aspirin and non-
aspirin (NA)-NSAIDs reduce risk of prostate cancer, and specifically risk of prostate cancer with 
lethal potential (Aim 1).  We also hypothesized that among men with prostate cancer, regular 
use of aspirin and NA-NSAIDs reduce risk of disease recurrence and case-fatality (Aim 2). 
Finally, we hypothesized that these effects are partially mediated by chronic intraprostatic 
inflammation, and that aspirin and NA-NSAID use would thus be associated with the presence 
and extent of inflammation in prostate tissue (Aim 3). To examine these relationships, we had to 




Chapter 2. Aspirin and Non-Aspirin NSAID Use and 
Prostate Cancer Incidence, Mortality, and Case-Fatality 








Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat pain 
and inflammation, and aspirin is recommended for some individuals for prevention of 
cardiovascular disease (CVD) and colorectal cancer. Observational studies suggest that 
NSAIDs may also lower risk of prostate cancer. However, there is limited evidence on whether 
NSAIDs protect against lethal prostate cancer in particular, and on whether benefits are 
consistent in black and white men. This study sought to determine the association between 
aspirin and non-aspirin NSAID (NA-NSAID) use and risk of total, lethal, and fatal prostate 
cancer and prostate cancer case-fatality, overall and by race, among men in the Atherosclerosis 
Risk in Communities (ARIC) study. 
Methods: The ARIC study enrolled individuals from four U.S. communities in 1987-89. This 
analysis was restricted to white and black men from this cohort who had information on 
medication use and who did not have a cancer history at baseline. Aspirin and NA-NSAID use 
was assessed at four study visits, with additional detailed information on aspirin use collected at 
the fourth study visit. Cancer outcomes were ascertained through 2012. Cox proportional 
hazards regression was used to estimate age- and multivariable-adjusted cause-specific hazard 
ratios (HRs) and 95% confidence intervals (CIs) for total incident prostate cancer, incident lethal 
prostate cancer, prostate cancer mortality (i.e. fatal prostate cancer), and case-fatality. Stratified 
models and likelihood ratio tests were used to test for effect modification by race. 
Results: There were 6,594 men (5,060 white, 1,534 black) at risk for prostate cancer. Aspirin 
and NA-NSAID use were not associated with total prostate cancer. However, aspirin use was 
inversely associated with lethal (HR: 0.58, 95% CI: 0.35-0.95) and fatal (HR: 0.59, 95% CI: 
0.36-0.96) prostate cancer. These associations were consistent among white and black men 
and most evident among men using aspirin regularly for CVD prevention. Aspirin use was also 
inversely associated with prostate cancer case-fatality (HR: 0.45, 95% CI: 0.22-0.94). NA-
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NSAID use was not associated with lethal or fatal prostate cancer, or with prostate cancer case-
fatality.  
Conclusions: Aspirin use was inversely associated with lethal and fatal prostate cancer, as well 
as case-fatality, among white and black men. If confirmed by additional research, benefits of 
aspirin pertaining to lethal prostate cancer may need to be factored into risk-benefit calculations 






 Unlike other leading causes of cancer, little is known about how to prevent prostate 
cancer. There is strong evidence that older age, African-American ancestry, and a positive 
family history increase risk of prostate cancer, but these risk factors are all non-modifiable. 
Cigarette smoking and obesity both appear associated with advanced and/or lethal prostate 
cancer (6, 7), but these risk factors can be difficult to modify. There is a need to identify 
additional modifiable risk factors for prostate cancer, and specifically for lethal prostate cancer, 
so that preventive strategies can be developed and morbidity and mortality can be reduced. 
 One potential modifiable factor is regular use of aspirin and non-aspirin (NA) 
nonsteroidal anti-inflammatory drugs (NSAIDs), which are hypothesized to prevent cancer 
incidence and progression via anti-inflammatory and anti-platelet mechanisms (80, 81). 
Secondary analyses of randomized controlled trials (RCTs) of aspirin for cardiovascular disease 
(CVD) have shown that daily aspirin reduces overall cancer incidence, development of cancer 
metastases, and cancer mortality, particularly after five or more years of use (33, 34, 37). 
However, RCTs have not been designed to examine effects of regular aspirin or NA-NSAID use 
on prostate cancer incidence and mortality specifically. 
 In observational studies, aspirin and NA-NSAID use have been associated with a 
moderately reduced risk of total prostate cancer (pooled odds ratio (POR) for aspirin: 0.83, 95% 
confidence interval (CI): 0.77-0.89; POR for NA-NSAIDs: 0.89, 95% CI: 0.78-1.02) (42). Aspirin 
but not NA-NSAID use has also been associated with a reduced risk of advanced prostate 
cancer (POR for aspirin: 0.81, 95% CI: 0.72-0.92) (42). However, most studies have defined 
advanced prostate cancer based on cancer stage or grade at diagnosis. Diagnostic stage and 
grade are imperfect indicators of disease lethality, particularly in settings with routine PSA 
screening for early detection and the resultant lead time (82, 83). Additional studies are thus 
needed to determine whether aspirin and NA-NSAID use protect against aggressive, potentially 
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lethal prostate cancer. Furthermore, previous studies have been conducted primarily among 
white men, and so generalizability to other groups is unknown. 
The goal of this study was to investigate associations between aspirin and NA-NSAID 
use and total, lethal, and fatal prostate cancer, overall and by race, among men who did not 
have a cancer history at baseline in the Atherosclerosis Risk in Communities (ARIC) study. This 
study also examined associations between aspirin and NA-NSAID use and prostate cancer 
case-fatality among men diagnosed with prostate cancer during ARIC follow-up. It was 
hypothesized that aspirin and NA-NSAID use would be inversely associated with these 




This study included men from the Atherosclerosis Risk in Communities (ARIC) study, a 
prospective cohort study that was designed to assess the etiology and natural history of CVD 
(84). A total of 15,792 men and women ages 45-64 years were recruited from four U.S. 
communities (Forsyth County, North Carolina; Jackson, Mississippi; the Minneapolis area, 
Minnesota; Washington County, Maryland) in 1987-89. Participants attended six in-person study 
visits (Visit 1: 1987-89, Visit 2: 1990-92, Visit 3: 1993-95, Visit 4: 1996-98, Visit 5: 2011-13, Visit 
6: 2016-17) and were interviewed by telephone annually. Each study field center received 
institutional review board approval, and all participants provided informed consent. 
For analyses of prostate cancer incidence and mortality, the study population was 
restricted to men without a history of cancer at their baseline visit in 1987-89 (Figure 2-1). The 
study population was further restricted to men who self-reported as either white or black, since 
race is an important determinant of prostate cancer incidence and mortality, and since there 
were not enough men of other racial groups to examine these groups separately. There were 
26 
 
also very few black men enrolled from the Washington County and Minneapolis field centers; 
these men were excluded as well, to avoid potential confounding by race/geography. Lastly, 
men with missing baseline medications data were excluded. 
For analyses of prostate cancer case-fatality, the study population included men 
diagnosed with prostate cancer during follow-up (1987-2012), irrespective of whether prostate 
cancer was the first or subsequent primary. Exclusion criteria were the same as above, with 
some additions: cases identified by death certificate only were excluded, as these men had no 
follow-up time post-diagnosis, and men missing diagnostic stage were also excluded, as stage 
is a critical covariate in case-fatality analyses.  
 
Assessment of Covariates 
At each study visit, participants were asked to bring in the containers for all medications 
that they had used within the past two weeks. Medication names, concentrations, source 
(prescribed, over-the-counter, or shared), and use over the past 24 hours were recorded. 
Current aspirin and NA-NSAID use were ascertained from these forms. See Appendix 2-1 for a 
detailed description of how the measure of current aspirin use was defined and validated.  
Additional information on regular aspirin use was collected at Visit 4. During this visit, 
participants were asked if they took aspirin on a regular basis, defined as use at least once a 
week for several months. If they responded yes, they were asked to provide the strength of the 
aspirin used (<300, 300-499, ≥500 mg), days per week of use, number of pills taken per week, 
their reason for taking aspirin, and the date that they began taking aspirin regularly. Participants 
were also asked whether they were currently taking aspirin regularly on annual follow-up 
interviews starting in 1998.  
Other covariates of interest, identified a priori as potential confounders and/or effect 
modifiers, included body mass index (BMI), cigarette smoking status, use of statin drugs, 
prevalent coronary heart disease (CHD), self-reported diabetes, use of diabetes medications, 
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serum glucose concentration (all assessed at each of the four study visits), glycated hemoglobin 
(ascertained at Visit 2), education level (ascertained at Visit 1), family history of prostate cancer 
(ascertained at Visit 3), and frequency of routine physical examinations (ascertained at Visit 2). 
Using these variables, diabetes status for each individual at each visit was classified as either 
diagnosed diabetes (self-reported diabetes or use of diabetes medications at the current visit, or 
any previous visit), undiagnosed diabetes (fasting serum glucose ≥126 mg/dL or non-fasting 
serum glucose ≥200 mg/dL), prediabetes (100 mg/dL ≤ fasting serum glucose <126 mg/dL, or 
140 mg/dL ≤ non-fasting serum glucose <200 mg/dL), or no diabetes (fasting serum glucose 
<100 mg/dL or non-fasting serum glucose <140 mg/dL). 
 
Outcome Ascertainment 
Cancer diagnoses and cancer deaths among study participants, as well as tumor 
characteristics, are identified and adjudicated through linkage to state cancer registries and 
review of hospital records and death certificates (85). Cancer outcomes are currently 
ascertained through 2012.   
For this study, there were four endpoints of interest: (1) total prostate cancer, defined as 
diagnosis of a first primary prostate cancer, (2) lethal prostate cancer, defined as diagnosis of a 
first primary prostate cancer that was advanced stage (T4, N1, or M1) at diagnosis or that 
caused death during follow-up, (3) fatal prostate cancer, defined as death from prostate cancer, 
irrespective of whether other cancers were also diagnosed during follow-up, and (4) prostate 
cancer case-fatality, defined as death from prostate cancer among men diagnosed with prostate 






For each exposure of interest and for each primary outcome, cause-specific hazard 
ratios (HRs) and 95% CIs comparing NSAID users to non-users were calculated via Cox 
proportional hazards regression.  For analyses of total prostate cancer, men were censored if 
lost-to-follow-up, if diagnosed with another cancer before prostate cancer, at death, or at end of 
follow-up in 2012. For analyses of lethal prostate cancer, men were also censored if they were 
diagnosed with a non-lethal prostate cancer. For analyses of fatal prostate cancer and prostate 
cancer case-fatality, men were censored at date of death from a cause other than prostate 
cancer, or administratively in 2012. For all models, the proportional hazards assumption was 
verified via Schoenfeld residuals. 
For analyses of current aspirin and NA-NSAID use and total, lethal, and fatal prostate 
cancer, age was the time metric and age 45 was the time origin. Aspirin and NA-NSAID use 
were treated as dichotomous exposures and updated at each study visit (through Visit 4). If 
missing, the last observed data point was carried forward. Other covariates included in the 
models were race/center (White/Forsyth, Black/Forsyth, Black/Jackson, White/Minneapolis, 
White/Washington County), birth cohort (in 5 year categories), smoking status (never, quit >10 
years ago, quit within 10 years or current smoker), BMI (continuous), statin use (yes, no), 
diabetes (diagnosed diabetes, undiagnosed diabetes, prediabetes, no diabetes), prevalent CHD 
(yes, no), years of education (basic [≤11 years], intermediate [12-16 years], advanced [≥17 
years]), and family history of prostate cancer (yes, no). Cigarette smoking status, BMI, statin 
use, diabetes, and CHD were treated as time-updated covariates; all other covariates were 
time-fixed. Time-updated covariates were also carried forward from the prior study visit when 
missing. When time-updated covariates were missing at Visit 1 or when time-fixed covariates 
were missing (0.2% missing for BMI, 0.2% for education, 2.0% for CHD, 7.4% for family history 
of prostate cancer, and 0.1% for diabetes), data were imputed using simple mean imputation.  
For analyses of regular aspirin use and total, lethal, and fatal prostate cancer, only men 
who responded to the questions on regular aspirin use and who did not have a cancer history at 
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Visit 4 were included. Age was the time metric, and the time origin was age 55 (the lower bound 
of the age range of participants at Visit 4, when information on regular aspirin use was 
ascertained). HRs were calculated comparing regular aspirin use, dose of aspirin use (<300, 
300-499, ≥500 mg), and indications for use (cardiovascular disease prevention, other) to no 
use. For these analyses, all aspirin variables and other covariates were treated as time-fixed 
and based on information collected at Visit 4.  
For analyses of prostate cancer case-fatality, prostate cancer diagnosis was the time 
origin and time since diagnosis was the time metric. For these analyses, the exposures of 
interest were aspirin and NA-NSAID use at the visit prior to prostate cancer diagnosis. All 
covariates were time-fixed and included age, stage (T1, T2, T3, T4), and grade (low, moderate, 
high, missing) at diagnosis, race/center, years between the prior ARIC study visit and prostate 
cancer diagnosis (continuous), birth cohort, education, family history of prostate cancer, and 
smoking status, BMI, statin use, diabetes, and prevalent CHD from the visit prior to prostate 
cancer diagnosis. 
To assess possible effect measure modification by race (white, black) and by frequency 
of routine physical examinations (≥ once every 5 years, < once every 5 years), analyses were 
repeated stratified by these variables. Statistical interaction was tested via the likelihood ratio 
test. To examine absolute differences in rates of each outcome among current aspirin and NA-
NSAID users and non-users, incidence rates were calculated using Poisson regression, with 
age category (45-54, 55-64, 65-74, 75-85 years), race, and aspirin or NA-NSAID use as 
covariates and robust variance estimation. 
Finally, several sensitivity analyses were conducted to verify the findings for current 
aspirin use and total, lethal, and fatal prostate cancer. First, because it was hypothesized that 
the influence of aspirin on cancer endpoints is not immediate, analyses were repeated with 
values for current aspirin use lagged one year. Aspirin use was only updated every three years 
and thus already lagged to some extent in the primary analysis, but this sensitivity analysis was 
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conducted to test whether additional lagging altered the findings. Second, because aspirin is 
often used concurrently with statins, and because statins have been associated with a reduced 
risk of total and advanced prostate cancer within ARIC (86) and other studies (87), analyses 
were repeated among non-statins users only. Too few men reported using both statins and 
aspirin to examine their joint effects. Third, to test the assumption that carrying forward the last 
observed value was an adequate approach for handling missing data on time-updated 
covariates, analyses were repeated with missing data imputed using multiple imputation by 
chained equations (MICE). Ten imputed datasets were derived, based on ten iterations each, 
with missing data predicted using all other covariates in this analysis. Finally, to examine the 
impact of current aspirin use on the cumulative incidence of each outcome, in the presence of 
competing events, subdistribution hazard ratios were calculated using Fine and Grey 
regression. Analyses were conducted in SAS Version 9.4 and R Version 3.4.  
 
Results 
There were 6,594 men who met study inclusion criteria. The mean age at Visit 1 was 54 
years old. Seventy-seven percent of the study population was white; 23% was black. Of these 
men, 5,976 (91%) attended Visit 2, 5,339 (81%) attended visit 3, and 4,821 (73%) attended Visit 
4. 
At Visits 1, 2, 3, and 4, 29% 33%, 37%, and 44% of men reported current aspirin use, 
respectively, while 13%, 16%, 20%, and 23% of men reported current NA-NSAID use. Patterns 
in current aspirin and NA-NSAID use across study visit are displayed in Figure 2-2. At Visit 4, 
37% of men reported regular aspirin use. Among regular aspirin users at Visit 4, 24% used baby 
aspirin (<300 mg), 68% used regular strength aspirin (300-499 mg) aspirin, and 4% used extra-
strength aspirin (≥500 mg). Eighty percent of regular aspirin users reported using aspirin for 
CVD prevention, while 20% reported using aspirin for other indications. 
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Through the end of 2012, 817 total incident prostate cancers, including 97 lethal prostate 
cancers, were diagnosed. There were 90 deaths from prostate cancer. 
 
Current Aspirin Use at Visits 1-4 and Total, Lethal, and Fatal Prostate Cancer 
Compared to non-users at Visit 1, current aspirin users were more likely to be white 
(90% vs. 72%) and have prevalent CHD (17% vs. 4%). Current aspirin users were also slightly 
more likely to have an advanced degree (45% vs. 37%), prediabetes (44% vs. 38%), and go in 
for a routine physical exam at least once every five years (66% vs. 59%, Table 2-1). 
After adjusting for potential confounders, there was no association between current 
aspirin use and total prostate cancer (HR: 1.05, 95% CI: 0.91-1.22). However, current aspirin 
use was inversely associated with both lethal prostate cancer (HR: 0.58, 95% CI: 0.35-0.95) and 
fatal prostate cancer (HR: 0.59, 95% CI: 0.36-0.96, Table 2-2). Results were consistent when 
current aspirin use was lagged by one year (Supplemental Table 2-1), when the analysis was 
restricted to non-users of statins (Supplemental Table 2-2), when missing data were imputed 
using multiple imputation (Supplemental Table 2-3) and when subdistribution hazard ratios were 
calculated (Supplemental Table 2-4). 
In race-stratified analyses, the association for total prostate cancer remained null for 
white men, but appeared positive for black men (HR: 1.30, 95% CI: 0.98-1.72, p-
interaction=0.13). For lethal prostate cancer, results were consistent across race (HR: 0.64, 
95% CI: 0.36-1.14 for white men; HR: 0.45, 95% CI: 0.16-1.29 for black men, p-
interaction=0.46). Similar results were observed for fatal prostate cancer (Table 2-3). 
When stratified by frequency of routine physical exams, current aspirin use was 
associated with a borderline significant increased risk of prostate cancer among men who 
reported frequent routine physical exams (HR: 1.18, 95% CI: 0.98-1.41). In contrast, there was 
a non-statistically significant inverse association between current aspirin use and total prostate 
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cancer among men who reported infrequent routine physical exams (HR: 0.85, 95% CI: 0.65-
1.10, p-interaction=0.07). Associations with lethal and fatal prostate cancer did not differ by 
routine physical exam frequency (Table 2-3). 
For all age and race categories, the incidence rate for lethal prostate cancer was lower 
among current aspirin users compared to non-users ( 
Figure 2-3). Incidence rate differences (IRDs) between current aspirin users and non-
users were greater among black men than white men (among men age 65-74 years: IRD: -51 
cases/100,000 person-years, 95% CI: -94- -8 for white men; IRD: -119 cases/100,000 person-
years, 95% CI: -213- -24 for black men). 
 
Regular Aspirin Use at Visit 4 and Total, Lethal, and Fatal Prostate Cancer 
 
There were 4,527 men who attended Visit 4, completed the questionnaire items on 
regular aspirin use, and were still at risk for the outcomes of interest (i.e. not yet diagnosed with 
any cancer, Table 2-4). Among these men, 506 total incident prostate cancers, 38 lethal 
prostate cancers, and 36 fatal prostate cancers were observed.  
Overall, regular aspirin use at Visit 4 was not statistically significantly associated with 
total (HR: 1.08, 95% CI: 0.89-1.32), lethal (HR: 0.95, 95% CI: 0.46-1.95), or fatal (HR: 0.81, 
95% CI: 0.38-1.70) prostate cancer (Table 2-5). When looked at by indication for use, aspirin 
used regularly for CVD prevention was not associated with total prostate cancer (HR: 1.04, 95% 
CI: 0.84-1.29) but was possibly inversely associated with lethal prostate cancer (HR: 0.63, 95% 
CI: 0.27-1.50) and fatal prostate cancer (HR: 0.57, 95% CI: 0.24-1.37, Table 2-6). Aspirin used 
regularly for other indications was non-significantly positively associated with all three 
outcomes. When looked at by dose of aspirin use, regular use of extra-strength aspirin was 
positively associated with total prostate cancer (HR: 1.84, 95% CI: 1.03-3.30, Table 2-7). For 
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lethal and fatal prostate cancer, low-dose and regular strength aspirin appeared to be 
associated with a reduced risk, while extra-strength aspirin appeared harmful.  
 
Current NA-NSAID Use at Visits 1-4 and Total, Lethal, and Fatal Prostate Cancer 
Men who reported current NA-NSAID use at Visit 1 were slightly older than non-users 
(55.0 vs. 54.4 years) and more likely to be white (82% vs. 76%, Table 2-8). Current NA-NSAID 
users were also slightly more likely to have prevalent CHD (10% vs. 8%) and diagnosed 
diabetes (9% vs. 7%). Current NA-NSAID users were more likely to go in for a routine physical 
examination at least once every five years (69% vs. 60%). 
In both age-adjusted and multivariable-adjusted models, there was no association 
between current NA-NSAID use and total, lethal, or fatal prostate cancer (Table 2-9). For total 
prostate cancer, the multivariable-adjusted HR was 1.16 (95%: CI 0.98-1.37). For lethal prostate 
cancer, the multivariable-adjusted HR was 0.85 (95% CI: 0.49-1.45), and for fatal prostate 
cancer, the multivariable-adjusted HR was 1.03 (95% CI: 0.62-1.71). No effect modification by 
race or frequency of routine physical exams was observed (Table 2-10). 
 
Aspirin and NA-NSAID Use and Prostate Cancer Case-Fatality 
 There were 676 men included in case-fatality analyses. Of these men, 6% were 
diagnosed with prostate cancer between Visit 1 and Visit 2, 9% were diagnosed between Visit 2 
and Visit 3, 16% were diagnosed between Visit 3 and Visit 4, and 69% were diagnosed after 
Visit 4. The mean age at diagnosis was 69 years, 82% were diagnosed with early stage disease 
(≤T2), and 69% were diagnosed with low or moderate grade disease (Gleason sum ≤7). Thirty-
nine percent of men reported using aspirin and 22% reported using NA-NSAIDs at the visit prior 
to diagnosis. Other demographic and clinical characteristics, by aspirin and NA-NSAID use, are 
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described in Table 2-11. Within this group of men, 65 deaths from prostate cancer were 
observed. 
 After multivariable adjustment, current aspirin use at the visit prior to diagnosis was 
inversely associated with prostate cancer case-fatality (HR: 0.45, 95% CI: 0.22-0.94). NA-
NSAID use was possibly inversely associated with case-fatality, but results were non-significant 
(HR: 0.69, 95% CI: 0.28-1.65). 
 
Discussion 
In this study population, current aspirin use was inversely associated with lethal and fatal 
prostate cancer, but not total prostate cancer. Inverse associations for regular aspirin use were 
only apparent for aspirin used for CVD prevention. Current aspirin use at the visit prior to 
diagnosis was also inversely associated with prostate cancer case-fatality. Current NA-NSAID 
use was not statistically significantly associated with any of the endpoints of interest. 
For current aspirin use, the magnitude of the associations with lethal and fatal prostate 
cancer were fairly large, with current aspirin users exhibiting a 42% reduced risk of lethal 
prostate cancer and 41% reduced risk of fatal prostate cancer relative to non-users. These 
inverse associations did not appear to be due to concurrent use of statins, as exclusion of 
current statin users did not affect the results. Two previous cohort studies also observed inverse 
associations between aspirin use and lethal prostate cancer: in the Health Professionals Follow-
up Study, the HR for lethal prostate cancer comparing current aspirin use to non-use was 0.84 
(95% CI: 0.69-1.02) (43), while in the Physicians’ Health Study, in which aspirin use was initially 
randomized and then offered to all participants after trial completion, the HR was 0.68 (95% CI: 
0.52-0.89) (44). Both of these studies included primarily white men. Importantly, our study 
extends these findings to black men, who are more likely than other racial/ethnic groups to 
develop and die from prostate cancer (1). In this study, we observed similar relative 
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associations for lethal and fatal prostate cancer across race, but a much greater association on 
the absolute scale among black men. Given that black men are less likely than white men to use 
aspirin, both in this study and in others (88, 89), encouraging guideline-concordant use of 
aspirin among black men may have the potential to help lower lethal prostate cancer rates 
among black men and attenuate the current racial disparity, if the association between aspirin 
use and lethal prostate cancer does prove to be causal. 
In analyses of regular aspirin use reported at Visit 4, inverse associations with lethal and 
fatal prostate cancer did not hold. It is unclear why these associations became null; there may 
have been loss of precision, due to the limited follow-up time after Visit 4 and the small number 
of events, or unknown sources of bias. However, compared to non-use, regular use of aspirin 
for CVD prevention and regular use of low- or standard-dose aspirin were possibly inversely 
associated with lethal and fatal prostate cancer. Though confidence intervals in these analyses 
were wide, these patterns indicate that the effect of aspirin on lethal prostate cancer may vary 
by dose or indication, a finding that warrants further investigation. 
At first glance, our null results for current aspirin use and total prostate cancer appear 
inconsistent with the prior literature, which has most often reported slight but significant inverse 
associations (42). However, our overall null results did not account for detection bias, i.e. bias 
resulting from the fact that NSAID users may be more health-conscious, or in greater contact 
with the healthcare system, and thus more likely to be screened for prostate cancer. Prior 
studies have shown that regular aspirin users are more likely to undergo prostate biopsy (14), 
and that accounting for detection bias leads to stronger inverse associations between aspirin 
use and total prostate cancer (42), and so detection bias in our study was likely. While our study 
was not able to adjust for prostate cancer screening history directly, we were able to stratify by 
frequency of routine visits to the doctor. We assumed that detection bias would be most evident 
among men who frequently visited the doctor for routine examinations, and who thus had 
greater opportunity to undergo prostate cancer screening, and minimal among men who 
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infrequently visited the doctor for routine examinations. Of note, the association among men 
who frequently visited the doctor was positive, consistent with the expected effect of detection 
bias, while the association among men who infrequently visited the doctor for physical 
examinations was moderately inverse. Though not statistically significant, the inverse 
association for men who infrequently visited their doctor for routine physical examinations is 
most consistent with prior studies and suggests that aspirin may protect against development of 
total prostate cancer, once the influence of detection bias is reduced.  
Current aspirin use at the visit prior to prostate cancer diagnosis was also associated 
with a 57% reduction in case-fatality. The inverse association remained despite adjustment for 
stage and grade at diagnosis, implying that the association was not simply due to earlier 
detection and increased lag time among aspirin users. This finding conflicts with the prior 
literature, which has consistently reported null associations between pre-diagnostic aspirin use 
and prostate cancer case-fatality (46-50). Our results may differ due to differing time intervals 
between measurement of aspirin use and prostate cancer diagnosis (median=5.7 years in our 
study vs. 1-3 years in the previous studies, with the exception of the study by Zhou et al. (50)), 
or differing study time frames (our study period overlapped both the pre-PSA and PSA era, 
while all previous studies were conducted solely in the PSA era). It is possible that aspirin is 
only beneficial earlier in the natural history of prostate cancer, several years before diagnosis, or 
that the predominance of indolent prostate cancer in the PSA era has obscured associations 
between pre-diagnostic aspirin use and survival among those with more aggressive disease. 
There could also be unmeasured confounding in our study by access to or receipt of treatment, 
a determinant of prostate cancer mortality that could potentially differ by aspirin use. Finally, our 
case-fatality analysis was limited by a small number of events, and further research is needed to 
explore whether our results were spurious, confounded, or indicative of a true causal 
relationship between pre-diagnostic aspirin use and prostate cancer death. 
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Current NA-NSAID use did not appear to be associated with total, lethal, or fatal prostate 
cancer or with prostate cancer case-fatality in this study population. The null associations for 
NA-NSAIDs, in contrast to the inverse associations for aspirin and lethal and fatal prostate 
cancer, could have several potential explanations. First, there may have been inadequate power 
to observe associations for NA-NSAID use, as there were fewer NA-NSAID users than aspirin 
users and thus fewer events among the NA-NSAID exposed. The group of NA-NSAID users 
was also likely a heterogeneous group, consisting of men using NA-NSAIDs for different 
indications and for different lengths of time. The mixing of regular users and sporadic users, 
including men using NA-NSAIDs short-term to alleviate acute pain, muscle pain, aches and pain 
due to colds, or headaches, could have biased results towards the null, as short-term use is 
unlikely to influence cancer outcomes. Finally, the discordant findings for aspirin and NA-
NSAIDs could indicate that any chemopreventive effects of aspirin against lethal prostate 
cancer are due to an aspirin-specific biological mechanism. For example, unlike other NSAIDs, 
aspirin has a prolonged inhibitory effect on platelets, which are thought to facilitate metastases 
through the bloodstream (30). If platelet inhibition is the primary mechanism of action through 
which aspirin protects against lethal prostate cancer, then similar effects for NA-NSAIDs would 
not be expected. Additional studies with greater power and detailed assessment of frequency 
and indication for NA-NSAID use are needed to rule out the first two explanations and provide 
support for or against the third. 
Aside from small sample size, the primary limitation of this study was the potential for 
misclassification of aspirin and NA-NSAID use. First, men were asked to self-report medication 
use by bringing bottles of all current medications to each study visit; failure to bring in all bottles 
could have resulted in underreporting of use. Second, medication use was assessed only at 
each study visit, and it was assumed that medication use remained constant during the three-
year interval between visits, or indefinitely after Visit 4. Third, though the effect of regular, long-
term use of aspirin and NA-NSAIDs was of most interest in this study, our definitions of current 
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aspirin and NA-NSAID use likely captured both short-term and long-term users. For aspirin, 
current use at Visit 4 was highly concordant with self-reported regular use at Visit 4, but 
concordance between current and regular NA-NSAID use was unknown. Fourth, additional 
information on dose, frequency of use, indication, and lifetime cumulative duration of use would 
have been informative, but these data were only available for aspirin at Visit 4. Finally, we did 
not have information on whether participants used aspirin or NA-NSAIDs prior to ARIC 
enrollment. Other limitations include the small number of lethal and fatal events, which limited 
power to detect more moderate effects and effects in stratified analyses, and the collinearity of 
race and US residence in this cohort, which limited our ability to tease apart the influence of 
race and geography.   
Despite this collinearity, the racial and geographic diversity of the cohort was a major 
study strength that improves generalizability of the results. There was also extremely thorough 
and time-updated assessment of potential CVD-related confounders. For example, body weight 
and height were measured at each study visit instead of self-reported, and diabetes status was 
assessed using a combination of self-report and markers of glycemia. Given that aspirin and 
NA-NSAIDs are used for specific indications and that these indications may share risk factors 
with total, lethal, or fatal prostate cancer, careful and complete adjustment for these risk factors 
is necessary to minimize confounding.  
In conclusion, this prospective, community-based study of white and black men provides 
evidence that aspirin may protect against development and progression of lethal prostate 
cancer. Additional studies are needed to build support for a causal relationship, and to continue 
to explore the influence of dose, duration, and timing of aspirin use. If confirmed, benefits of 
aspirin pertaining to lethal prostate cancer could eventually be incorporated into clinical 
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Chapter 2 Tables 
 
Table 2-1. Baseline (1987-1989) demographic and clinical characteristics of 6,594 men in 
the ARIC study, by current aspirin use  
 Current Aspirin Use at 
Visit 1 
  No Yes 
N  4743 1851 
Age, mean (sd) 54.3 (5.8) 54.9 (5.6) 
BMI, mean (sd) 27.4 (4.2) 27.8 (4.3) 
Race, n (%)   
   White  3403 (72) 1675 (90) 
   Black  1340 (28) 194 (10) 
Center, n (%)   
   Forsyth 1207 (25) 524 (28) 
   Jackson 1188 (25) 153 (8) 
   Minneapolis 1136 (24) 666 (36) 
   Washington County 1212 (26) 508 (27) 
Cigarette Smoking Status, n (%)   
   Current/Recent (quit <10 years ago) 2084 (44) 810 (44) 
   Former (quit ≥10 years ago) 1285 (27) 572 (31) 
   Never  1374 (29) 469 (25) 
Education, n (%)   
   Basic 1242 (26) 356 (19) 
   Intermediate 1734 (37) 659 (36) 
   Advanced 1756 (37) 834 (45) 
   Missing 11 (0) 2 (0) 
Family History of PCa*, n (%)   
   Yes  275 (6) 100 (5) 
   No  4121 (87) 1608 (87) 
   Missing 347 (7) 143 (8) 
Statin Use**, n (%)   
   Yes  17 (0) 20 (1) 
   No  4726 (100) 1831 (99) 
Prevalent CHD, n (%)   
   Yes  209 (4) 322 (17) 
   No  4431 (93) 1501 (81) 
   Missing 103 (2) 28 (2) 
Diabetes, n (%)   
   Diagnosed diabetes 342 (7) 138 (7) 
   Undiagnosed diabetes 213 (4) 80 (4) 
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   Prediabetes 1790 (38) 809 (44) 
   No diabetes 2391 (50) 824 (45) 
   Missing   
Frequency of Routine Physical 
Examinations 
  
   ≥Once every 5 years 2779 (59) 1230 (66) 
   <Once every 5 years 1949 (41) 620 (34) 
   Missing 15 (0) 1 (0) 
sd, standard deviation; BMI, body mass index; PCa, prostate cancer; CHD, coronary heart disease 
*Reported at Visit 3 
**Statin use is low at baseline because the first statin was not FDA approved until 1987. For a better comparison of 





Table 2-2. Associations between current aspirin use and total, lethal, and fatal prostate 
cancer among 6,594 men in the ARIC study, 1987-2012 









Total Prostate Cancer     
No Aspirin  503 / 75897 1.00 -- 1.00 -- 
Aspirin 314 / 43478 0.96 (0.84, 1.11) 1.05 (0.91, 1.22) 
      
Lethal Prostate Cancer     
No Aspirin  74 / 76025 1.00 -- 1.00 -- 
Aspirin 23 / 43572 0.48 (0.30, 0.77) 0.58 (0.35, 0.95) 
      
Fatal Prostate Cancer     
No Aspirin  65 / 84565 1.00 -- 1.00 -- 
Aspirin 25 / 48951 0.52 (0.33, 0.82) 0.59 (0.36, 0.96) 
*Adjusted for race/center (White/Forsyth, Black/Forsyth, Black/Jackson, White/Minneapolis, White/Washington 
County), birth cohort (in 5 year categories), smoking status (current/recent, former, never), BMI (continuous), current 
statin use (yes, no), diabetes (diagnosed diabetes, undiagnosed diabetes, prediabetes, no diabetes), prevalent CHD 





Table 2-3. Associations between current aspirin use and total, lethal, and fatal prostate cancer among 6,594 men in the 
ARIC study, 1987-2012, stratified by race and frequency of routine physical examinations 




























Total Prostate Cancer           
No Aspirin  316 / 55777 1.00 -- 1.00 -- 187 / 20120 1.00 -- 1.00 --  
Aspirin 243 / 38271 1.00 (0.85, 1.18) 0.97 (0.82, 1.16) 71 / 5207 1.28 (0.97, 1.68) 1.30 (0.98, 1.72) 0.13 
            
Lethal Prostate Cancer           
No Aspirin  40 / 55898 1.00 -- 1.00 -- 34 / 20127 1.00 -- 1.00 --  
Aspirin 19 / 38365 0.62 (0.36, 1.07) 0.64 (0.36, 1.14) 4 / 5207 0.40  (0.14, 1.12) 0.45 (0.16, 1.29) 0.46 
            
Fatal Prostate Cancer           
No Aspirin  36 / 62036 1.00 -- 1.00 -- 29 / 22529 1.00 -- 1.00 --  
Aspirin 21 / 42823 0.66 (0.39, 1.14) 0.67 (0.38, 1.19) 4 / 6127 0.39 (0.14, 1.10) 0.41 (0.14, 1.20) 0.32 
            
 Frequent Routine Physical Examinations*** Infrequent Routine Physical Examinations*** 
p-
value* 

























Total Prostate Cancer           
No Aspirin  298 / 43895 1.00 -- 1.00 -- 205 / 31730 1.00 -- 1.00 --  
Aspirin 223 / 27806 1.06 (0.89, 1.26) 1.18 (0.98, 1.41) 91 / 15643 0.79 (0.62, 1.02) 0.85 (0.65, 1.10) 0.07 
            
Lethal Prostate Cancer           
No Aspirin  41 / 43974 1.00 -- 1.00 -- 33 / 31778 1.00 -- 1.00 --  
Aspirin 14 / 27856 0.48 (0.26, 0.88) 0.56 (0.30, 1.06) 9 / 15686 0.50 (0.24, 1.04) 0.64 (0.30, 1.39) 0.95 
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Fatal Prostate Cancer           
No Aspirin  38 / 49264 1.00 -- 1.00 -- 27 / 35010 1.00 -- 1.00 --  
Aspirin 14 / 31508 0.46 (0.25, 0.86) 0.49 (0.26, 0.94) 11 / 17412 0.62 (0.31, 1.26) 0.78 (0.37, 1.63) 0.49 
*p-value is from the likelihood ratio test comparing the multivariable model with vs. without an interaction term between aspirin use and race/frequency of routine 
physical exams 
**Adjusted for race/center (White/Forsyth, Black/Forsyth, Black/Jackson, White/Minneapolis, White/Washington County), birth cohort (in 5 year categories), 
smoking status (current/recent, former, never), BMI (continuous), current statin use (yes, no), diabetes (diagnosed diabetes, undiagnosed diabetes, prediabetes, 
no diabetes), prevalent CHD (yes, no, missing), education (basic, intermediate, advanced, missing), family history of prostate cancer (yes, no, missing) 
***Frequent routine physical examination defined as an examination at least once every 5 years, infrequent routine physical examination defined as an examination 
less that once every 5 years or no routine physical 
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Table 2-4. Visit 4 (1996-1998) demographic and clinical characteristics of 4,527 men in the 
ARIC study, by regular aspirin use 
 Current Aspirin Use at 
Visit 4 
  No Yes 
N  2852 1675 
Age, mean (sd) 62.4 (5.7) 63.8 (5.6) 
BMI, mean (sd) 28.4 (4.6) 28.6 (4.4) 
Race, n (%)   
   White  2188 (77) 1496 (89) 
   Black  664 (23) 179 (11) 
Center, n (%)   
   Forsyth 678 (24) 435 (26) 
   Jackson 601 (21) 163 (10) 
   Minneapolis 778 (27) 582 (35) 
   Washington County 795 (28) 495 (30) 
Cigarette Smoking Status, n (%)   
   Current/Recent (quit <10 years ago) 838 (29) 454 (27) 
   Former (quit ≥10 years ago) 1107 (39) 731 (44) 
   Never  907 (32) 490 (29) 
Education, n (%)   
   Basic 589 (21) 284 (17) 
   Intermediate 1073 (38) 611 (36) 
   Advanced 1183 (41) 777 (46) 
   Missing 7 (0) 3 (0) 
Family History of PCa*, n (%)   
   Yes  183 (6) 113 (7) 
   No  2664 (93) 1556 (93) 
   Missing 5 (0) 6 (4) 
Statin Use, n (%)   
   Yes  186 (7) 399 (24) 
   No  2666 (93) 1276 (76) 
Prevalent CHD, n (%)   
   Yes  101 (4) 363 (22) 
   No  2696 (95) 1284 (77) 
   Missing 55 (2) 28 (2) 
Diabetes, n (%)   
   Diagnosed diabetes 329 (12) 288 (17) 
   Undiagnosed diabetes 149 (5) 82 (5) 
   Prediabetes 1131 (40) 650 (39) 
   No diabetes 1243 (44) 655 (39) 
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Frequency of Routine Physical Exams   
   ≥ Once every 5 years 1656 (58) 1077 (64) 
   < Once every 5 years 1190 (42) 597 (36) 
   Missing 6 (0) 1 (0) 
sd, standard deviation; BMI, body mass index; PCa, prostate cancer; CHD, coronary heart disease 





Table 2-5. Associations between regular aspirin use at Visit 4 and total, lethal, and fatal 
prostate cancer among 4,527 men in the ARIC study, 1996-2012 









Total Prostate Cancer     
No Aspirin  321 / 34363 1.00 -- 1.00 -- 
Aspirin 185 / 19097 1.03 (0.86, 1.23) 1.09 (0.89, 1.32) 
      
Lethal Prostate Cancer     
No Aspirin  24 / 34410 1.00 -- 1.00 -- 
Aspirin 14 / 19119 1.01 (0.52, 1.96) 0.95 (0.46, 1.95) 
      
Fatal Prostate Cancer     
No Aspirin  23 / 38667 1.00 -- 1.00 -- 
Aspirin 13 / 21663 0.86 (0.44, 1.70) 0.81 (0.38, 1.70) 
*Adjusted for race/center (White/Forsyth, Black/Forsyth, Black/Jackson, White/Minneapolis, White/Washington 
County), birth cohort (in 5 year categories), smoking status at Visit 4 (current/recent, former, never), BMI at Visit 4 
(continuous), statin use at Visit 4 (yes, no), diabetes at Visit 4 (diagnosed diabetes, undiagnosed diabetes, 
prediabetes, no diabetes), prevalent CHD at Visit 4 (yes, no, missing), education (basic, intermediate, advanced, 




Table 2-6. Associations between indication for regular aspirin use at Visit 4 and total, 
lethal, and fatal prostate cancer among 4,527 men in the ARIC study, 1996-2012 









Total Prostate Cancer     
No Aspirin  321 / 34363 1.00 -- 1.00 -- 
Aspirin for CVD 
prevention 
142 / 15101 1.00 (0.82, 1.21) 1.04 (0.84, 1.29) 
Aspirin for other 
indication 
43 / 3925 1.16  (0.84, 1.60) 1.25 (0.91, 1.73) 
      
Lethal Prostate Cancer     
No Aspirin  24 / 34410 1.00 -- 1.00 -- 
Aspirin for CVD 
prevention 
8 / 15111 0.73 (0.33, 1.62) 0.63 (0.27, 1.50) 
Aspirin for other 
indication 
6 / 3938 2.11 (0.86, 5.15) 2.31 (0.92, 5.80) 
      
Fatal Prostate Cancer     
No Aspirin  23 / 38667 1.00 -- 1.00 -- 
Aspirin for CVD 
prevention 
8 / 17140 0.65 (0.29, 1.56) 0.57 (0.24, 1.37) 
Aspirin for other 
indication 
5 / 4452 1.76 (0.67, 4.63) 1.83 (0.68, 4.89) 
*Adjusted for race/center (White/Forsyth, Black/Forsyth, Black/Jackson, White/Minneapolis, White/Washington 
County), birth cohort (in 5 year categories), smoking status at Visit 4 (current/recent, former, never), BMI at Visit 4 
(continuous), statin use at Visit 4 (yes, no), diabetes at Visit 4 (diagnosed diabetes, undiagnosed diabetes, 
prediabetes, no diabetes), prevalent CHD at Visit 4 (yes, no, missing), education (basic, intermediate, advanced, 
missing), family history of prostate cancer (yes, no, missing) 
5 aspirin users of unknown indication were excluded
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Table 2-7. Associations between dose of regular aspirin use at Visit 4 and total, lethal, 
and fatal prostate cancer among 4,527 men in the ARIC study, 1996-2012 










Total Prostate Cancer      
No Aspirin  321 / 34363 1.00 -- 1.00 -- 
Baby Aspirin 47 / 4499 1.10 (0.81, 1.49) 1.15 (0.84, 1.58) 
Regular Strength 120 / 13170 0.97 (0.78, 1.19) 1.03 (0.82, 1.29) 
Extra Strength Aspirin 12 / 800 1.58 (0.89, 2.82) 1.85 (1.04, 3.32) 
      
Lethal Prostate Cancer     
No Aspirin  24 / 34410 1.00 -- 1.00 -- 
Baby Aspirin 3 / 4501 0.91 (0.28, 3.04) 0.78 (0.22, 2.71) 
Regular Strength 8 / 13191 0.83 (0.37, 1.85) 0.79 (0.34, 1.87) 
Extra Strength Aspirin 2 / 800 3.50 (0.83, 14.84) 3.86 (0.86, 17.20) 
      
Fatal Prostate Cancer      
No Aspirin  23 / 38667 1.00 -- 1.00 -- 
Baby Aspirin 2 / 5211 0.56 (0.13, 2.37) 0.49 (0.11, 2.17) 
Regular Strength 8 / 14834 0.75 (0.34, 1.69) 0.71 (0.30, 1.71) 
Extra Strength Aspirin 2 / 922 3.33 (0.78, 14.10) 3.38 (0.75, 15.28) 
*Adjusted for race/center (White/Forsyth, Black/Forsyth, Black/Jackson, White/Minneapolis, White/Washington 
County), birth cohort (in 5 year categories), smoking status at Visit 4 (current/recent, former, never), BMI at Visit 4 
(continuous), statin use at Visit 4 (yes, no), diabetes at Visit 4 (diagnosed diabetes, undiagnosed diabetes, 
prediabetes, no diabetes), prevalent CHD at Visit 4 (yes, no, missing), education (basic, intermediate, advanced, 
missing), family history of prostate cancer (yes, no, missing) 
Baby aspirin = <300mg, regular aspirin = 300-499mg, extra strength aspirin = ≥500mg 




Table 2-8. Baseline (1987-1989) demographic and clinical characteristics of 6,594 men in 
the ARIC study, by current NA-NSAID use 
 Current NA-NSAID Use at 
Visit 1 
  No Yes 
N  5718 876 
Age, mean (sd) 54.4 (5.8) 55.0 (5.8) 
BMI, mean (sd) 27.4 (4.2) 28.4 (4.6) 
Race, n (%)   
   White  4340 (76) 720 (82) 
   Black  1378 (24) 156 (18) 
Center, n (%)   
   Forsyth 1477 (26) 254 (29) 
   Jackson 1459 (26) 261 (30) 
   Minneapolis 1219 (21) 122 (14) 
   Washington County 1563 (27) 239 (27) 
Cigarette Smoking Status, n (%)   
   Current/Recent (quit <10 years ago) 2523 (44) 371 (42) 
   Former (quit ≥10 years ago) 1570 (27) 287 (33) 
   Never  1625 (28) 218 (25) 
Education, n (%)   
   Basic 1371 (24) 277 (26) 
   Intermediate 2059 (36) 334 (38) 
   Advanced 2275 (40) 315 (36) 
   Missing 13 (0) 0 (0) 
Family History of PCa*, n (%)   
   Yes  319 (6) 56 (6) 
   No  4977 (87) 752 (86) 
   Missing 422 (7) 68 (8) 
Aspirin Use, n (%)   
   Yes  1623 (28) 228 (26) 
   No  4095 (72) 648 (74) 
Statin Use**, n (%)   
   Yes  29 (1) 8 (1) 
   No  5689 (99) 868 (99) 
Prevalent CHD, n (%)   
   Yes  441 (8) 90 (10) 
   No  5163 (90) 769 (88) 
   Missing 114 (2) 17 (2) 
Diabetes, n (%)   
   Diagnosed diabetes 401 (7) 79 (9) 
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   Undiagnosed diabetes 245 (4) 48 (5) 
   Prediabetes 2246 (39) 353 (40) 
   No diabetes 2822 (49) 393 (45) 
   Missing 4 (0) 3 (0) 
Frequency of Routine Physical Exams   
   ≥ Once every 5 years 3405 (60) 604 (69) 
   < Once every 5 years 2299 (40) 270 (31) 
   Missing 14 (0) 2 (0) 
NA-NSAID, non-aspirin nonsteroidal anti-inflammatory drug; sd, standard deviation; BMI, body mass index; PCa, 
prostate cancer; CHD, coronary heart disease 
*Reported at Visit 3 






Table 2-9. Associations between current NA-NSAID use and total, lethal, and fatal 
prostate cancer among 6,594 men in the ARIC study, 1987-2012 









Total Prostate Cancer     
No NA-NSAID  633 / 96626 1.00 -- 1.00 -- 
NA-NSAID 184 / 22749 1.15 (0.98, 1.36) 1.16 (0.98, 1.37) 
      
Lethal Prostate Cancer     
No NA-NSAID  81 / 96799 1.00 -- 1.00 -- 
NA-NSAID 16 / 22797 0.79 (0.46, 1.34) 0.85 (0.49, 1.45) 
      
Fatal Prostate Cancer     
No NA-NSAID  71 / 107724 1.00 -- 1.00 -- 
NA-NSAID 19 / 25792 1.02 (0.62, 1.70) 1.02 (0.62, 1.71) 
NA-NSAID, non-aspirin nonsteroidal anti-inflammatory drug 
*Adjusted for race/center (White/Forsyth, Black/Forsyth, Black/Jackson, White/Minneapolis, White/Washington 
County), birth cohort (in 5 year categories), smoking status (current/recent, former, never), BMI (continuous), current 
statin use (yes, no), diabetes (diagnosed diabetes, undiagnosed diabetes, prediabetes, no diabetes), prevalent CHD 





Table 2-10. Associations between current NA-NSAID use and total, lethal, and fatal prostate cancer among 6,594 men in the 
ARIC study, 1987-2012, stratified by race and frequency of routine physical examinations 
 White Men Black Men 
p-
value* 

























Total Prostate Cancer           
No NA-NSAID 428 / 75450 1.00 -- 1.00 -- 205 / 21176 1.00 -- 1.00 --  
NA-NSAID 131 / 18597 1.18 (0.97, 1.44) 1.17 (0.96, 1.43) 53 / 4151 1.15 (0.85, 1.55) 1.13 (0.83, 1.54) 0.81 
            
Lethal Prostate Cancer           
No NA-NSAID 50 / 75617 1.00 -- 1.00 -- 31 / 21182 1.00 -- 1.00 --  
NA-NSAID 9 / 18646 0.70 (0.35, 1.43) 0.74 (0.36, 1.52) 7 / 4151 0.99 (0.44, 2.25) 1.14 (0.50, 2.62) 0.66 
            
Fatal Prostate Cancer           
No NA-NSAID 47 / 83945 1.00 -- 1.00 -- 24 / 23780 1.00 -- 1.00 --  
NA-NSAID 10 / 20915 0.82 (0.41, 1.61) 0.79 (0.40, 1.58) 9 / 4877 1.43 (0.66, 3.09) 1.71 (0.78, 3.76) 0.33 
            
 Frequent Routine Physical Examinations*** Infrequent Routine Physical Examinations*** 
p-
value* 

























Total Prostate Cancer           
No NA-NSAID 397 / 57433 1.00 -- 1.00 -- 236 / 39193 1.00 -- 1.00 --  
NA-NSAID 124 / 14569 1.17 (0.96, 1.43) 1.16 (0.94, 1.42) 60 / 8179 1.12 (0.84, 1.48) 1.20 (0.90, 1.60) 0.95 
            
Lethal Prostate Cancer           
No NA-NSAID 44 / 57542 1.00 -- 1.00 -- 37 / 39257 1.00 -- 1.00 --  
NA-NSAID 11 / 14590 0.94 (0.48, 1.81) 1.03 (0.53, 2.01) 5 / 8208 0.60 (0.23, 1.52) 0.69 (0.27, 1.76) 0.39 
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Fatal Prostate Cancer           
No NA-NSAID 41 / 64362 1.00 -- 1.00 -- 30 / 43362 1.00 -- 1.00 --  
NA-NSAID 11 / 16732 0.97 (0.50, 1.89) 0.98 (0.50, 1.92) 8 / 9060 1.13 (0.52, 2.46) 1.16 (0.52, 2.57) 0.90 
NA-NSAID, non-aspirin nonsteroidal anti-inflammatory drug 
*p-value is from the likelihood ratio test comparing the multivariable model with vs. without an interaction term between NA-NSAID use and race/frequency of 
routine physical exams 
**Adjusted for race/center (White/Forsyth, Black/Forsyth, Black/Jackson, White/Minneapolis, White/Washington County), birth cohort (in 5 year categories), 
smoking status (current/recent, former, never), BMI (continuous), current statin use (yes, no), diabetes (diagnosed diabetes, undiagnosed diabetes, prediabetes, 
no diabetes), prevalent CHD (yes, no, missing), education (basic, intermediate, advanced, missing), family history of prostate cancer (yes, no, missing) 
***Frequent routine physical examination defined as an examination at least once every 5 years, infrequent routine physical examination defined as an examination 
less that once every 5 years or no routine physical
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Table 2-11. Demographic and clinical characteristics of 676 men diagnosed with prostate 
cancer in the ARIC study, 1987-2012, by current aspirin and NA-NSAID use at the visit 
prior to diagnosis 
 Current Aspirin Use Current NA-NSAID Use 
  No Yes No Yes 
N  411 265 530 146 
Age at Diagnosis, mean (sd) 69.0 (6.2) 69.4 (6.5) 69.0 (6.2) 69.6 (6.5) 
BMI, mean (sd) 28.0 (4.3) 28.5 (4.1) 28.1 (4.4) 28.4 (3.7) 
Race, n (%)     
   White 294 (72) 223 (84) 395 (76) 122 (84) 
   Black 117 (28) 42 (16) 135 (25) 24 (16) 
Center, n (%)     
   Forsyth 123 (30) 66 (25) 143 (27) 46 (32) 
   Jackson 97 (24) 39 (15) 115 (22) 21 (14) 
   Minneapolis 99 (24) 79 (30) 133 (25) 45 (31) 
   Washington County 92 (22) 81 (31) 139 (26) 34 (23) 
Cigarette Smoking Status, n (%)     
Current/Recent (quit <10 years 
ago) 
123 (30) 62 (23) 151 (28) 34 (23) 
   Former (quit ≥10 years ago) 154 (37) 115 (43) 205 (39) 64 (44) 
   Never  134 (33) 88 (33) 174 (33) 48 (33) 
Education, n (%)     
   Basic 88 (21) 43 (16) 104 (20) 27 (18) 
   Intermediate 159 (39) 94 (35) 202 (38) 51 (35) 
   Advanced 164 (40) 128 (48) 224 (42) 68 (47) 
Family History of PCa, n (%)     
   Yes  47 (11) 32 (12) 57 (11) 22 (15) 
   No  357 (87) 229 (86) 462 (87) 124 (85) 
   Missing 7 (2) 4 (2) 11 (2) 0 (0) 
Statin Use, n (%)     
   Yes  17 (4) 47 (18) 48 (9) 16 (11) 
   No  394 (96) 218 (82) 482 (91) 130 (89) 
Prevalent CHD, n (%)     
   Yes  11 (3) 51 (19) 55 (10) 7 (5) 
   No  390 (95) 209 (79) 464 (88) 135 (92) 
   Missing 10 (2) 5 (2) 11 (2) 4 (3) 
Diabetes, n (%)     
   No diabetes 178 (43) 114 (43) 232 (44) 60 (41) 
   Diagnosed diabetes 32 (8) 31 (12) 51 (10) 12 (8) 
   Undiagnosed diabetes 17 (4) 20 (8) 31 (6) 6 (4) 
   Prediabetes 184 (45) 100 (38) 216 (41) 68 (47) 
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Frequency of Routine Physical 
Exams 
    
   ≥ Once every five years 245 (60) 185 (70) 334 (63) 96 (66) 
   < Once every five years 166 (40) 80 (30) 196 (37) 50 (34) 
Cancer Stage (Clinical or 
Pathologic) 
    
   T1 22 (5) 10 (4) 23 (4) 9 (6) 
   T2 or SEER Summary Stage 1 314 (76) 208 (78) 405 (76) 117 (80) 
   T3 or SEER Summary Stage 2 47 (11) 36 (14) 67 (13) 16 (11) 
T4 or SEER Summary Stage 3, 4,       
or 7 
28 (7) 11 (4) 35 (7) 4 (3) 
Cancer Grade at Diagnosis     
   Low 96 (23) 49 (18) 112 (21) 33 (23) 
   Moderate 187 (46) 135 (51) 245 (46) 77 (53) 
   High 109 (27) 74 (28) 149 (28) 34 (23) 
   Missing 19 (5) 7 (3) 24 (5) 2 (1) 
NA-NSAID, non-aspirin nonsteroidal anti-inflammatory drug; sd, standard deviation; BMI, body mass index; PCa, 




Table 2-12. Associations between current aspirin and NA-NSAID use at the visit prior to 
diagnosis and prostate cancer case-fatality among 676 men diagnosed with prostate 



















Aspirin Use       
No 49 / 3417 1.00 -- 1.00 -- 1.00 -- 
Yes 16 / 2275 0.49 (0.28, 0.86) 0.55 (0.29, 1.05) 0.45 (0.22, 0.94) 
NA-NSAID Use       
No 57 / 4535 1.00 -- 1.00 -- 1.00 -- 
Yes 8 / 1157 0.55 (0.26, 1.16) 0.76 (0.33, 1.72) 0.69 (0.28, 1.65) 
NA-NSAID, non-aspirin nonsteroidal anti-inflammatory drug 
*Adjusted for age at diagnosis, stage (T1, T2, T3, T4), grade (low, moderate, high, missing), race/center 
(White/Forsyth, Black/Forsyth, Black/Jackson, White/Minneapolis, White/Washington County), and years between the 
prior ARIC study visit and diagnosis 
**Adjusted for age at diagnosis, stage (T1, T2, T3, T4), grade (low, moderate, high, missing), race/center 
(White/Forsyth, Black/Forsyth, Black/Jackson, White/Minneapolis, White/Washington County), years between the 
prior ARIC study visit and diagnosis, birth cohort (in 5 year categories), smoking status (current/recent, former, 
never), BMI (continuous), current statin use (yes, no), diabetes (diagnosed diabetes, undiagnosed diabetes, 
prediabetes, no diabetes), prevalent CHD (yes, no, missing), education (basic, intermediate, advanced, missing), 




Chapter 2 Figures  
 
 
Figure 2-1. Study Inclusion Criteria. The primary analysis was restricted to men from the 
ARIC study without a prevalent cancer at baseline and with non-missing data on medication use 
at baseline. Individuals identifying as a race other than white or black, and black men from the 




Figure 2-2. Patterns in Current Aspirin and NA-NSAID Use. Patterns in aspirin and NA-
NSAID use across the four study visits are shown in the lasagna plots above. When aspirin or 
NA-NSAID use was unknown, values were carried forward from the previous visit (as indicated 
by the lighter shading). Overall, there were more current aspirin than NA-NSAID users at each 
study visit. Once initiating aspirin use, men were more likely to continue using aspirin for the 






Figure 2-3. Incidence Rates for Lethal Prostate Cancer for Men in the ARIC Study, 1987-
2012, by Age, Race, and Current Aspirin Use. For all age and race categories, incidence 
rates for lethal prostate cancer were lower among current aspirin users as compared to non-
users. However, absolute differences in incidence rates between aspirin and non-aspirin users 
were more pronounced for black men. For example, for white men ages 65-74, the difference in 
incidence rates of lethal prostate cancer between aspirin users and non-users was -51 cases 
per 100,000 person-years (95% CI: -94, -8). For black men ages 65-74, the difference was -119 

































Appendix 2-1. Comparison and Validation of Aspirin Variables in ARIC 
 
There were several variables that we could have used to define current aspirin use at ARIC 
Visits 1-4. The ARIC datasets included a derived variable on aspirin use during the two weeks 
prior to each study visit, created using medication codes for the medication bottles that 
participants brought with them to each study visit. For this variable, participants were considered 
an aspirin user if they brought in a medication that fit one of the following codes: 
 
"641000" = “SALICYLATES” 
"641099" = “SALICYLATE COMBINATIONS” 
"642000" = “ANALGESICS OTHER” 
"642099" = “ANALGESICS - OTHER COMBINATIONS” 
"649900" = “ANALGESIC COMBINATIONS” 
"649910" = “ANALGESIC-SEDATIVES” 
"649920" = “ANALGESIC-ANTICHOLINERGICS” 
"659900" = “NARCOTIC COMBINATIONS” 
"659910" = “CODEINE COMBINATIONS” 
"659913" = “DIHYDROCODEINONE COMBINATIONS” 
"659917" = “HYDROCODONE COMBINATIONS” 
"659920" = “PROPOXYPHENE COMBINATIONS” 
"659930" = “MEPERIDINE COMBINATIONS” 
"659940" = “PENTAZOCINE COMBINATIONS” 
  
However, because this variable likely captured aspirin use as well as use of other non-aspirin 
analgesics, a second derived variable was created. This variable defined aspirin users as 
individuals who brought in medications fitting the following two codes only: 
 
"641000" = “SALICYLATES” 
"641099" = “SALICYLATE COMBINATIONS” 
 
Finally, we considered use of a third variable based on self-reported use of aspirin, cold 
medication, or headache powder during the two weeks prior to each study visit. 
 
For the purpose of this study, we were most interested in long-term, regular use of aspirin, and 
not short-term or sporadic use for treatment of headaches, colds, or acute pain. Thus, to 
determine which of these variables best captured regular aspirin use, we compared values for 
these three variables at visit 4 (V4) to our “gold standard” measure: self-reported regular aspirin 
use at V4. We selected the variable with the highest concordance, and the best balance of 






1. Self-reported regular aspirin use at V4 (“gold standard”) 
2. Original derived variable for aspirin use within the past two weeks, based on medication 
codes, for V1-V4 
3. Modified derived variable for aspirin use within the past two weeks, based on medication 
codes (modified to exclude codes for drug combinations that do not necessarily contain 
aspirin), for V1-V4 
4. Self-reported use of aspirin, cold medication, or headache powder within the past two 
weeks, for V1-V4 
 
Concordance between variables 1 & 2 at V4: 
 
 Variable 1 
Variable 2 No Yes Total 
No 1882 35 1917 
Yes 954 1638 2592 
Total 2836 1673 4509 
 





Concordance between variables 1 & 3 at V4: 
 
 Variable 1 
Variable 3 No Yes Total 
No 2422 95 2517 
Yes 412 1578 1990 
Total 2834 1673 4507 
 





Concordance between variables 1 & 4 at V4: 
 
 Variable 1 
Variable 4 No Yes Total 
No 2097 37 2134 
Yes 734 1638 2372 
Total 2831 1675 4506 
 







Appendix 2-2. Supplemental Tables 
 
Supplemental Table 2-1. Associations between current aspirin use lagged by one year 
and total, lethal, and fatal prostate cancer among 6,594 men in the ARIC study, 1987-2012 









Total Prostate Cancer     
No Aspirin  508 / 72009 1.00 -- 1.00 -- 
Aspirin 301 / 40821 0.94 (0.81, 1.08) 1.03 (0.88, 1.20) 
      
Lethal Prostate Cancer     
No Aspirin  75 / 72137 1.00 -- 1.00 -- 
Aspirin 20 / 40915 0.42 (0.26, 0.69) 0.52 (0.31, 0.87) 
      
Fatal Prostate Cancer     
No Aspirin  67 / 80662 1.00 -- 1.00 -- 
Aspirin 23 / 46284 0.47 (0.29, 0.75) 0.52 (0.32, 0.86) 
*Adjusted for race/center (White/Forsyth, Black/Forsyth, Black/Jackson, White/Minneapolis, White/Washington 
County), birth cohort (in 5 year categories), smoking status (current/recent, former, never), BMI (continuous), current 
statin use (yes, no), diabetes (diagnosed diabetes, undiagnosed diabetes, prediabetes, no diabetes), prevalent CHD 
(yes, no, missing), education (basic, intermediate, advanced, missing), family history of prostate cancer (yes, no, 
missing) 




Supplemental Table 2-2. Associations between current aspirin use and total, lethal, and 
fatal prostate cancer among 6,594 men in the ARIC study, 1987-2012, restricted to non-
current users of statins 









Total Prostate Cancer     
 No Aspirin  479 / 73272 1.00 -- 1.00 -- 
 Aspirin 265 / 37629 0.97 (0.83, 1.12) 1.06 (0.90, 1.24) 
      
Lethal Prostate Cancer     
No Aspirin  73 / 73400 1.00 -- 1.00 -- 
Aspirin 19 / 37720 0.46 (0.27, 0.75) 0.54 (0.32, 0.91) 
      
Fatal Prostate Cancer     
No Aspirin  63 / 81493 1.00 -- 1.00 -- 
Aspirin 20 / 42074 0.49 (0.30, 0.81) 0.56 (0.33, 0.95) 
*Adjusted for race/center (White/Forsyth, Black/Forsyth, Black/Jackson, White/Minneapolis, White/Washington 
County), birth cohort (in 5 year categories), smoking status (current/recent, former, never), BMI (continuous), 
diabetes (diagnosed diabetes, undiagnosed diabetes, prediabetes, no diabetes), prevalent CHD (yes, no, missing), 




Supplemental Table 2-3. Associations between current aspirin use and total, lethal, and 
fatal prostate cancer among 6,594 men in the ARIC study, 1987-2012, with missing data 
imputed via multiple imputation 









Total Prostate Cancer     
No Aspirin  504 / 75881 1.00 -- 1.00 -- 
Aspirin 313 / 43494 0.97 (0.84, 1.11) 1.06 (0.91, 1.23) 
      
Lethal Prostate Cancer     
No Aspirin  74 / 76008 1.00 -- 1.00 -- 
Aspirin 23 / 43588 0.48 (0.30, 0.76) 0.58 (0.35, 0.94) 
      
Fatal Prostate Cancer     
No Aspirin  65 / 84546 1.00 -- 1.00 -- 
Aspirin 25 / 48970 0.52 (0.33, 0.82) 0.59 (0.36, 0.96) 
*Adjusted for race/center (White/Forsyth, Black/Forsyth, Black/Jackson, White/Minneapolis, White/Washington 
County), birth cohort (in 5 year categories), smoking status (current/recent, former, never), BMI (continuous), current 
statin use (yes, no), diabetes (diagnosed diabetes, undiagnosed diabetes, prediabetes, no diabetes), prevalent CHD 





Supplemental Table 2-4. Associations between current aspirin use and cumulative 
incidence of total, lethal, and fatal prostate cancer, accounting for non-prostate cancer 
death as a competing event, among 6,594 men in the ARIC study, 1987-2012 









Total Prostate Cancer     
No Aspirin  503 / 75897 1.00 -- 1.00 -- 
Aspirin 314 / 43478 0.89 (0.77, 1.02) 0.99 (0.86, 1.15) 
      
Lethal Prostate Cancer     
No Aspirin  74 / 76025 1.00 -- 1.00 -- 
Aspirin 23 / 43572 0.51 (0.34, 0.77) 0.63 (0.42, 0.94) 
      
Fatal Prostate Cancer     
No Aspirin  65 / 84565 1.00 -- 1.00 -- 
Aspirin 25 / 48951 0.54 (0.35, 0.82) 0.62 (0.41, 0.95) 
*Adjusted for race/center (White/Forsyth, Black/Forsyth, Black/Jackson, White/Minneapolis, White/Washington 
County), birth cohort (in 5 year categories), smoking status (current/recent, former, never), BMI (continuous), current 
statin use (yes, no), diabetes (diagnosed diabetes, undiagnosed diabetes, prediabetes, no diabetes), prevalent CHD 





Chapter 3. Aspirin and Non-Aspirin NSAID Use and 








Background: Use of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs (NA-NSAIDs) 
has been associated with a reduced risk of developing certain cancers, including prostate 
cancer. However, associations with prostate cancer outcomes following diagnosis are unclear. 
This study examined associations between aspirin and NA-NSAID use and prostate cancer 
recurrence in a clinical cohort of prostate cancer patients treated surgically. 
Methods: The study population included patients with clinically localized prostate cancer who 
underwent surgery between 1993 and 2006 by a single surgeon at the Johns Hopkins Hospital. 
Medication use was systematically solicited during the preoperative consultation and later 
abstracted from patient medical records. Medications used ≥2 times per week pre- and post-
surgery were also ascertained via a survey mailed to surviving men in 2007. Patients were 
followed through 2014 for prostate cancer recurrence, defined as biochemical recurrence, local 
recurrence, development of metastatic disease, or prostate cancer death. Cox proportional 
hazards regression was used to estimate associations between aspirin and NA-NSAID use (at 
the preoperative consult, pre-surgery, and post-surgery) and recurrence, adjusted for age, 
pathologic stage, grade, and potential confounders. Effect modification by stage/grade and year 
of surgery was assessed using stratified models. 
Results: There were 2,364 men in the full cohort, and 1,508 men who completed the 2007 
survey. Among men in the full cohort, 9.69% used aspirin and 5.67% used an NA-NSAID at the 
preoperative consultation. After multivariable adjustment, aspirin use (HR: 1.16, 95% CI: 0.79-
1.69) and NA-NSAID use (HR: 1.06, 95% CI: 0.64-1.75) at the preoperative consultation were 
not associated with recurrence. Among men who completed the survey, aspirin use pre-surgery 
(HR 1.14, 95% CI 0.75-1.72) and post-surgery (HR 1.25, 95% CI 0.83-1.89), and NA-NSAID 
use pre-surgery (HR 0.84, 95% CI 0.50-1.41) and post-surgery (1.29, 95% CI 0.83-2.00) were 
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also not associated with recurrence. Results were overall consistent when stratified by 
stage/grade and year of surgery.   
Conclusions: Within this study population, aspirin and NA-NSAID use at various time intervals 
were not inversely associated with recurrence in men treated with radical prostatectomy for 






There are currently more than three million prostate cancer survivors living in the U.S. 
(90). Prostate cancer often has a favorable prognosis, and the vast majority of men with 
prostate cancer live for years, or even decades, after their initial diagnosis. However, some may 
experience disease recurrence after treatment and/or progression to metastatic disease. 
Identification of modifiable risk factors for prostate cancer recurrence and progression may 
provide a means for lowering the risk of these outcomes, in conjunction with conventional 
treatments and management strategies.  
One potential modifiable risk factor for prostate cancer recurrence is regular use of 
aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). These drugs are hypothesized 
to reduce risk of cancer progression via anti-inflammatory and antiplatelet mechanisms. 
Specifically, inhibition of COX-2 blocks production of pro-inflammatory prostaglandins that 
promote cell proliferation, angiogenesis, and invasion, while inhibition of COX-1 impedes 
platelets, which are thought to facilitate metastases through the bloodstream (30, 80, 91). In 
support of these hypotheses, secondary analyses of randomized controlled trials have found 
that allocation to daily aspirin reduces overall cancer mortality (37) and risk of cancer with 
distant metastases, both at initial presentation and at follow-up (34). 
For prostate cancer, the literature on aspirin and non-aspirin NSAID (NA-NSAID) use 
and cancer outcomes following diagnosis has been mixed. Observational studies of aspirin use 
pre-diagnosis and prostate cancer case-fatality have largely been null (46-50), though an 
inverse association was observed in the Atherosclerosis Risk in Communities study (see 
Chapter 2 of this dissertation). Studies of aspirin use post-diagnosis and case-fatality have 
reported results ranging from null (46, 48-50, 53, 79), to protective (44, 52, 78), to harmful (51). 
Few studies have reported specifically on NA-NSAID use and prostate cancer outcomes (49, 
50, 53). Moreover, very few studies have been able to examine prostate cancer recurrence as 
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an outcome. Prostate cancer recurrence, typically marked by biochemical recurrence (BCR), i.e. 
rising PSA after PSA nadir post-radical prostatectomy, often precedes death from prostate 
cancer by several years, and may thus be an early indicator of poor disease outcome less 
subject to bias due to differential access to salvage treatments or competing risks.  
The purpose of this study was to investigate whether aspirin and NA-NSAID use were 
associated with risk of prostate cancer recurrence among a cohort of men surgically treated for 
prostate cancer at the Johns Hopkins Hospital (JHH). We hypothesized that aspirin and NA-
NSAID use reported at the time of the preoperative consultation, pre-surgery, and-post-surgery 






This secondary data analysis included men treated with radical prostatectomy by a 
single surgeon at JHH. All men were diagnosed with clinically localized disease, and all 
underwent radical prostatectomy between January 1, 1993 and March 31, 2006. This study 
period was chosen to restrict to men both diagnosed in the post-PSA era and eligible for the 
2007 survey. Men who underwent hormone or radiation therapy before radical prostatectomy 
were excluded. The study was approved by institutional review boards at the Johns Hopkins 
University School of Medicine and Johns Hopkins Bloomberg School of Public Health. 
 
Ascertainment of NSAID Use and Other Covariates 
Age, race/ethnicity, first-degree family history of prostate cancer, preoperative PSA, year 
of surgery, positive surgical margins, pathologic stage, and Gleason sum are routinely 
abstracted for patients undergoing radical prostatectomy at JHH. To obtain information on 
medication use and comorbidities at the time of the preoperative consultation, electronic and 
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paper medical records pertaining to this visit were also reviewed by a single abstractor blinded 
to outcome. During the preoperative consultation, the surgeon routinely asked about and 
recorded current use of aspirin and NA-NSAIDs in patient medical records, as use of these 
drugs conferred an increased risk of bleeding during the surgery. 
Men alive as of November 2007 and residing in the United States were also mailed a 
survey on lifestyle and medical factors. The survey ascertained additional information about 
over-the-counter or prescription medications used regularly, defined as use more than two times 
per week. Specifically, men were asked to self-report whether they regularly used specific 
medications (aspirin, ibuprofen, other anti-inflammatory analgesics, acetaminophen, statins, and 
other cholesterol-lowering drugs) pre- and/or post-surgery (yes, no), and if yes, the duration of 
use (<1 year, 1-4 years, 5-9 years, or 10+ years) pre- and post-surgery. Men also self-reported 
their height, weight (five years before surgery, one-year post-surgery, and current), and 
cigarette smoking history (including number of cigarettes smoked daily at several age intervals).  
 
Outcome Ascertainment 
The primary outcome for this analysis was prostate cancer recurrence after radical 
prostatectomy, defined as a composite outcome of BCR, local recurrence, metastasis, or death 
from prostate cancer (whichever outcome occurred first). As a secondary outcome, time to 
metastatic prostate cancer was also examined. To monitor for disease recurrence, men were 
evaluated by their primary care physicians with PSA tests and digital-rectal examinations every 
3 months for the first year after surgery, semiannually during the second year, and annually 
thereafter. BCR was defined as a confirmed PSA value ≥0.2 ng/mL after PSA nadir. Prostate 
cancer deaths were determined through linkage to the National Death Index. For this analysis, 





Age-adjusted baseline characteristics of the cohort were compared by aspirin and NA-
NSAID use at the preoperative consultation, and by pre-surgical use reported via the survey. 
Cox proportional hazards regression was then used to calculate cause-specific hazard ratios 
(HRs) and 95% confidence intervals (CIs) for recurrence comparing users versus non-users of 
aspirin and NA-NSAIDs. Three sets of analyses were conducted: 
 
1) Using data from the medical record abstraction, aspirin and NA-NSAID users at the time of 
the preoperative consultation were compared to non-users of aspirin and NA-NSAIDs, 
respectively. In these analyses, year of surgery was the time origin and years since surgery was 
the time metric. All men in the cohort were included. Covariates were obtained from the medical 
record abstraction and included and categorized as age (continuous), year of surgery 
(continuous), race (white, nonwhite), pathologic stage (<T3, ≥T3), pathologic grade (Gleason 
sum <4+3, ≥4+3), body mass index (BMI) (<25, 25-30, ≥30 kg/m2, missing), use of a statin at 
the time of the preoperative consultation (yes, no), history of cardiovascular disease (CVD) (yes, 
no), and history of arthritis (yes, no).  
 
2) Using data from the 2007 survey, associations for ever use of aspirin pre-surgery, ever use of 
aspirin post-surgery, ever use of NA-NSAIDs pre-surgery, and ever use of NA-NSAIDs post-
surgery were examined in separate models. For pre-surgical use of aspirin and NA-NSAIDs, 
duration of use (categorized as <1 year, 1-4 years, 5-9 years, 10+ years) was also considered. 
Joint categories of pre- and post-surgical use (never use, use pre-surgery only, use post-
surgery only, and use pre- and post-surgery) were examined to assess for potential interaction. 
For all of these models, the time metric was years since surgery and the time origin was one-
year post-surgery (since certain covariates, such as BMI and smoking status, were assessed 
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one-year post-surgery, and because it was assumed that events occurring within one year were 
not truly recurrent events but evidence of more advanced disease at the time of diagnosis). Men 
who completed the 2007 survey, who were at risk for the event one-year post-surgery (i.e. did 
not recur or were not lost to follow-up at one year), and who had non-missing medications data 
were included. Models were adjusted for age, year of surgery, race, pathologic stage, pathologic 
grade, history of CVD, or arthritis (from the medical record abstraction, treated as above), and 
BMI one-year post-surgery (continuous), weight change from five-years pre-surgery to one-year 
post-surgery (>2.2, ≤2.2 kg, missing), cigarette smoking status one-year post-surgery (current, 
former, never, missing), and use of statins pre-surgery (yes, no, missing) from the 2007 survey.  
 
3) The analyses from 2) were repeated with 2007 (the year of administration of the survey) as 
the time origin, and years since 2007 as the time metric. This analysis was conducted to remove 
potential effects of recall bias, as all events included in this analysis were ascertained 
prospectively in relation to the survey. All men who completed the 2007 survey, had non-
missing medications data, and were still at risk for recurrence in 2007 (i.e. had not recurred prior 
to 2007) were included. Models were adjusted for the same set of covariates as above. 
 
 Covariates for these models were chosen a priori, based on prior studies from within this 
cohort and other cohorts. Covariates included age, established risk factors for prostate cancer 
recurrence (race) and factors that had previously been associated with recurrence in this cohort 
(smoking status, BMI, weight change from five years before surgery to one year after surgery, 
use of statins) (92-94). Models were also adjusted for indications for aspirin and NA-NSAID use, 
including history of CVD and history of arthritis, since these conditions are associated with 
aspirin and NA-NSAID use and may share risk factors with prostate cancer recurrence. Year of 
surgery was included in the models to account for possible secular trends and, in the latter two 
analyses, for the differing amounts of elapsed time between surgery and survey administration. 
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Finally, models were adjusted for pathologic stage and grade, since the goal of this analysis 
was to determine whether aspirin and NA-NSAID use influence risk of prostate cancer 
outcomes independent of disease severity at diagnosis and surgery. 
For all analyses, men were censored at the date of death or last known follow-up. The 
proportional hazards assumption was tested through Schoenfeld residuals and plots of the log 
cumulative hazard function. Stratified analyses were used to test for possible effect measure 
modification by stage and grade at surgery (stage ≥T3 or Gleason sum ≥4+3 vs. stage <T3 and 
Gleason sum <4+3) and by year of surgery (pre-2000 vs. post-2000). To examine our 
secondary outcome of prostate cancer metastases, models were repeated with time to 




Aspirin and NA-NSAID use at the time of the preoperative consultation and 
prostate cancer recurrence 
 
There were 2,364 men in the full cohort. The mean age at surgery was 56 years. The 
majority of men were white and had non-advanced disease at surgery. 9.69% of the cohort used 
aspirin at the time of the pre-surgical consultation and 5.67% used NA-NSAIDs. After adjusting 
for age, most baseline characteristics were similar among aspirin users and non-users at the 
time of the preoperative consultation, with the exception of statin use and history of CVD and 
arthritis, which were all more prevalent among aspirin users (Table 3-1). Compared to non-
users, NA-NSAID users were more likely to have high-grade disease at surgery and a history of 
arthritis, after adjusting for age (Table 3-1).  
During 25,622 person-years at risk, 300 recurrence events were observed. These 
recurrences included 185 men who experienced biochemical recurrence only, 25 with local 
recurrences, and 84 who developed metastatic prostate cancer. There were 48 deaths from 
prostate cancer in this cohort, and 28 deaths from other causes but with prostate cancer 
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progression. The median time to recurrence after surgery was 4 years, while the median time to 
metastatic prostate cancer after surgery was 7 years. 
Overall, aspirin and NA-NSAID use at the time of the preoperative consultation were not 
associated with prostate cancer recurrence (for aspirin: HR: 1.16, 95% CI: 0.79-1.69; for NA-
NSAIDs: HR: 1.06, 95% CI: 0.64-1.75, Table 3-2). Results remained null when stratified by 
stage and grade at diagnosis and by year of diagnosis (Table 3-3). Aspirin and NA-NSAID use 
at the time of the preoperative consultation were also not associated with prostate cancer 
metastasis (for aspirin: HR: 1.00, 95% CI: 0.48-2.07; for NA-NSAIDs: HR: 1.16, 95% CI: 0.48-
2.79, Table 3-4). 
 
Aspirin and NA-NSAID use pre- and post-surgery and prostate cancer 
recurrence, with time at risk beginning one-year post-surgery 
 
There were 1505 men (64% of the full cohort) who returned the survey in 2007. A 
comparison of men who did vs. did not complete the survey is presented in Table 3-5. 
Compared to the men who did not respond or were ineligible to receive the survey (i.e. died 
before 2007 or no longer resided in the U.S.), the survey respondents were older, had more 
favorable clinical characteristics at diagnosis (less advanced stage and lower PSA values), were 
more likely to be white, and less likely to have a history of CVD. Of the 1505 survey 
respondents, 20 were not at risk for recurrence one-year post-surgery (including 19 who 
recurred and one who was lost to follow-up within one year of surgery) and were consequently 
excluded from further analyses. 
Of the 1485 men, 41.8% reported regular aspirin use pre-surgery and 55.0% reported 
regular aspirin use post-surgery. 24.6% used NA-NSAIDs pre-surgery, and 28.7% used NA-
NSAIDs post-surgery. Age-adjusted characteristics by aspirin and NA-NSAID use pre-surgery 




After adjusting for stage and grade at surgery and potential confounders, regular aspirin 
use pre-surgery was not associated with prostate cancer recurrence (HR: 1.29, 95% CI: 0.91-
1.82, Table 3-7). Associations did not vary by duration of pre-surgical use. Regular use of 
aspirin post-surgery was associated with a borderline-significant increased risk of recurrence 
(HR: 1.37, 95% CI: 0.96-1.96).  When joint categories of aspirin use pre- and post-surgery were 
examined, the elevated risk of recurrence was most apparent in men who reported using aspirin 
both pre- and post-surgery, compared to the reference group of never users (HR: 1.47, 95% CI:  
0.99-2.19). For both pre- and post-surgical aspirin use, associations were similar when stratified 
by stage/grade at surgery, but more positive among men undergoing surgery after 2000 (for 
pre-surgical aspirin: HR: 2.39, 95% CI: 1.20-4.77; for post-surgical aspirin: HR: 2.02, 95% CI:  
0.99-4.11, Table 3-8). 
No associations were observed between regular NA-NSAID use pre-surgery (HR: 0.96, 
95% CI:  0.64-1.45) or post-surgery (HR: 1.20, 95% CI: 0.84-1.71) and recurrence. Joint use of 
NA-NSAIDs both pre- and post-surgery was also not associated with recurrence (HR: 1.23, 95% 
CI: 0.80-1.88). No effect modification by stage/grade or year of surgery was observed. 
Null associations were observed for all exposures and the secondary outcome of 
prostate cancer metastasis (pre-surgical aspirin: HR: 0.89, 95% CI: 0.43-1.82; post-surgical 
aspirin: HR: 1.17, 95% CI: 0.56-2.43); pre-surgical NA-NSAIDs: HR: 0.73, 95% CI: 0.30-1.77; 
post-surgical NA-NSAIDs: HR: 0.65, 95% CI: 0.30-1.41, Table 3-11). 
 
Aspirin and NA-NSAID use pre- and post-surgery and prostate cancer 
recurrence, with time at risk beginning in 2007 
 
There were 1363 men still at risk for prostate cancer recurrence in 2007 (90% of survey 
respondents, and 58% of the full cohort). Age-adjusted characteristics of these men by aspirin 
and NA-NSAID use pre-surgery are shown in Table 3-12.  Among these men, there were 57 
recurrences and 9 metastases. 
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In this analysis, aspirin use pre-surgery was positively associated with prostate cancer 
recurrence (HR: 2.05, 95% CI: 1.13-3.72, Table 3-13). Similar results were observed among all 
categories of duration of use pre-surgery. Aspirin use post-surgery was also positively 
associated with recurrence (HR: 2.22, 95% CI: 1.18-4.16). The positive association was 
strongest among men who reported aspirin use both pre- and post-surgery, compared to never 
users of aspirin (HR: 2.61, 95% CI: 1.31-5.19). When stratified by year of surgery, the positive 
association was most apparent among men treated with surgery after 2000 (for aspirin use pre-
surgery: HR: 3.08, 95% CI: 1.31-7.26; for aspirin use post-surgery: HR: 2.47, 95% CI 1.02-6.01, 
Table 3-14), similar to the analyses with time at risk beginning one-year post-surgery. 
Null associations were observed for NA-NSAID use pre-surgery (HR: 0.92, 95% CI: 
0.46-1.82), post-surgery (HR: 1.19, 955 CI: 0.66-2.15), and both pre- and post-surgery (HR: 
1.16, 95% CI: 0.56-2.41) and prostate cancer recurrence (Table 3-15). There were not enough 
events among NA-NSAID users to conduct stratified analyses. There were also not enough 




In this study, neither aspirin nor NA-NSAID use was inversely associated with prostate 
cancer recurrence, as was hypothesized. Instead, our results suggest null, or possibly positive, 
associations between aspirin use pre- and post-surgery and recurrence, even after adjustment 
for key confounders. For both pre- and post-surgical aspirin use, positive associations were 
most evident when the analysis was restricted to men undergoing surgery after 2000, who were 
recalling medication use over a shorter time frame and who thus may have been less like to 
misremember their medications history. Positive associations were also observed in the 
analyses with time at risk beginning in 2007, in which only events occurring prospectively in 
relation to the survey were included. We did not observe associations between NA-NSAID use 
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at any time point and recurrence, or between aspirin or NA-NSAID use and prostate cancer 
metastases, though power in these analyses was limited. 
Our results for aspirin were somewhat surprising given our hypotheses, our findings on 
aspirin use pre-diagnosis and prostate cancer case-fatality in Chapter 2, and the prior literature, 
which has most often reported null (46-50, 53, 79) or inverse (44, 52, 78) associations between 
aspirin use pre- and post-diagnosis and prostate cancer outcomes. One previous population-
based study using a national prescription-drug database in the United Kingdom did find a 
positive association between post-diagnostic aspirin use and prostate cancer case-fatality, but 
the increased risk was only observed among men initiating aspirin use after diagnosis, and it is 
possible that these men initiated aspirin to combat adverse side effects of treatments for 
prostate cancer that had already recurred or progressed (51). Prior studies of aspirin use and 
prostate cancer outcomes have also shown evidence of effect modification by cancer stage and 
grade. Specifically, studies have reported inverse associations that were more pronounced (47, 
52) or only observed (48) among men with advanced stage or grade prostate cancer. These 
findings were not replicated in this study, as our results for aspirin were consistent across strata 
of pathologic stage and grade. Our results are however consistent with the few preceding 
studies of NA-NSAID use and prostate cancer outcomes, which have also reported null 
associations (50, 53). 
There are several possible reasons why aspirin use might appear positively correlated 
with recurrence. In the analyses of pre-surgical aspirin use, pre-surgical use may have 
prevented some cancers from developing or from being diagnosed. Aspirin use has been 
associated with a slight to moderate decreased risk of prostate cancer in observational studies 
(42) as well as decreased PSA (95), which could lower the likelihood of prostate cancer 
detection. Prostate cancers that do develop or that release enough PSA to prompt detection, 
despite aspirin use, may thus be more aggressive and likely to recur, which could make pre-
surgical aspirin use appear harmful. It is also possible that aspirin use during these time 
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intervals, instead of reducing inflammation, may have actually impeded existing inflammation 
from resolving, as has been shown in some animal models (17). Finally, due to the 
observational nature of this study, we cannot rule out confounding by unmeasured factors 
related to both indications for aspirin use and prostate cancer outcomes, or other sources of 
bias as discussed below.  
This study included three distinct analyses, each with its own strengths and potential 
biases: 
 
Aspirin and NA-NSAID use at the time of the preoperative consultation and 
prostate cancer recurrence 
 
The first analysis, with exposure data collected via medical record abstraction, had both 
a clearly-defined cohort (men undergoing surgery for prostate cancer by a single surgeon 
between 1993-2006) and exposure (aspirin and NA-NSAID use at the time of the pre-surgical 
consultation). This analysis also had the advantage of being fully prospective, as aspirin and 
NA-NSAID use were recorded in the medical records in real-time, prior to prostate cancer 
treatment and outcomes. However, there may have been exposure misclassification due to 
possible underreporting of aspirin and NA-NSAID use. The prevalence of aspirin and NA-NSAID 
use in this analysis was low compared to the prevalence of aspirin and NA-NSAID use reported 
via the 2007 survey. In part, the lower prevalence may be due to aspirin and NA-NSAID use 
being ascertained at a very specific time point, as opposed to the survey, which asked about 
regular aspirin use more generally at any time prior to surgery. Due to the prospective nature of 
this analysis, any misclassification of exposure should have been non-differential with respect to 
prostate cancer recurrence, and would bias the results predictably towards the null.   
 
Aspirin and NA-NSAID use pre- and post-surgery and prostate cancer 




The analysis of NSAID use pre- and post-surgery based on the survey data, with time at 
risk beginning one-year post-surgery, had the advantage of using the more detailed information 
on aspirin and NA-NSAID use collected via the survey. As a result, this analysis was able to 
examine pre- and post-surgical NSAID use separately, as well as duration of use pre-surgery. 
However, this analysis was not fully prospective, as the 2007 survey was administered after 
men had already been followed for several years and after some had already recurred. Results 
from this analysis may have thus been affected by recall bias. Specifically, biased positive 
associations between NSAID use and recurrence could have arisen if men who recurred before 
2007 were more likely to remember and/or report NSAID use than the men who remained 
recurrence-free at the time of the 2007 survey.  
This analysis was also subject to selection bias due to the fact that men had to survive to 
2007 and respond to the mailed survey in order to be included. Men who returned the survey 
may have differed in key ways from the men who died prior to 2007 (from prostate cancer or 
from other causes) or who failed to respond to the survey request. Some differences between 
survey respondents and non-respondents were observed (Table 3-5) and could be accounted 
for in multivariable models, but survey respondents and non-respondents may have differed in 
unmeasured ways as well. For additional discussion of selection bias, see Appendix 3-1. 
Finally, in the analysis of post-surgical NSAID use and recurrence with time at risk 
beginning one-year post-surgery, there was possible misallocation of person-time. Post-surgical 
NSAID use was treated as a time-fixed covariate in this analysis due to the lack of information 
on start and stop dates of medication use. However, men who reported post-surgical NSAID 
use may not have used NSAIDs for the entirety of their post-surgical follow-up, and so it is likely 
that person-time at risk, and possibly even events, were misallocated to the exposed group 




Aspirin and NA-NSAID use pre- and post-surgery and prostate cancer 
recurrence, with time at risk beginning in 2007 
 
Our third analysis, with time at risk beginning in 2007, was designed to maintain the 
strengths and circumvent some of the biases of the previous analysis. This analysis was 
restricted to men who were still at risk for recurrence in 2007; as a result, all outcomes included 
in this analysis occurred prospectively in relation to the 2007 survey and recall bias was 
avoided. Misallocation of person-time was also not an issue, as ever use of NSAIDs post-
surgery, but pre-2007 survey, could appropriately be treated as time-fixed. However, the time 
origin in this analysis was 2007, which is a less meaningful origin than the origin used in the first 
two analyses (year of surgery). This analysis also included an even more selected group of 
men, and selection bias was consequently more likely. In this analysis, men not only had to 
survive to complete the 2007 survey, but they also had to remain recurrence-free in 2007. The 
median time from surgery to recurrence in the full cohort was 4 years, and so men who had not 
yet experienced a recurrence in 2007, 1-14 years after their prostate cancer surgery, may have 
had much more favorable-risk prostate cancer than the men who recurred prior to 2007 and 
were excluded. Ideally, we would have been able to restrict this analysis to men treated in the 
few years prior to 2007 to limit the potential impact of this survival bias, but power was too low 
to conduct the analysis in this manner.   
 
For all three analyses, generalizability of the results may be limited. First, the source 
population was narrowly defined as men undergoing surgical treatment for clinically-localized 
prostate cancer by a single surgeon at JHH between 1993 and 2006. The results may thus only 
be applied to men with prostate cancer who undergo surgery or are good candidates for surgical 
treatment, i.e. men with non-metastatic disease and few to no comorbidities. The patient 
population seeking care at JHH is also a selected population, consisting primarily of white men 
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of high socioeconomic status. Generalizability to other racial groups or socioeconomic strata is 
thus unknown. 
At the same time, the homogeneity of the study population is an important study 
strength. Because all men in the cohort received the same prostate cancer treatment at the 
same hospital by the same surgeon, there should be little to no confounding by access to 
medical care or variability in healthcare quality. There was consistent recording of medication 
use in the preoperative consultation medical records of all patients, and consistent capturing of 
prostate cancer outcomes. Though it is likely that both methods for ascertaining medications 
use (the medical record abstraction and the mailed survey) had some measurement error, and 
though our three analyses were subject to different potential biases, the relatively consistency in 
findings across exposure ascertainment and analytic methods provide credence to our results. 
In summary, our study does not provide support for an inverse association between 
aspirin and NA-NSAID use pre- or post-surgery and prostate cancer recurrence after surgery. 
These results suggest that aspirin and NA-NSAIDs should not be recommended to patients to 
improve prostate cancer outcomes, but given the conflicting findings for aspirin across study, 
additional large, well-designed observational studies or randomized controlled trials are still 
warranted. 
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Chapter 3 Tables 
 
Table 3-1. Age-adjusted characteristics of the full cohort at the preoperative consultation, 
by aspirin and NA-NSAID use at the preoperative consultation, Johns Hopkins Hospital 
Radical Prostatectomy Cohort 
 
 Aspirin Use NA-NSAID Use 
  No Yes p-value No Yes p-value 
N  2135 229  2230 134  
Age, years, mean 56.0 58.7 <0.01 56.3 57.0 0.26 
Year of surgery, mean  1999.1 1999.1 1.0 1999.1 1999.7 0.05 
PSA value, ng/mL, mean  6.9 6.9 0.9 6.9 7.4 0.2 
Pathologic stage, %       
   <T3  72 68 0.2 72 69 0.4 
   ≥T3 28 32  28 31  
Pathologic grade (Gleason 
sum), % 
      
   <4+3  90 89 0.6 90 83 <0.01 
   ≥4+3  10 11  10 17  
Race, %       
   White  93 92 0.3 93 93 0.3 
   Black  3 2  3 4  
   Other/Missing 4 7  5 3  
BMI, %       
   <25 kg/m2  32 33 0.08 33 30 0.2 
   25 - <30 kg/m2  52 58  53 52  
   ≥30 kg/m2  11 7  11 12  
   Missing 4 2  4 6  
Family history of PCa, %       
   Yes  35 33 0.8 35 40 0.6 
   No  60 60  60 56  
   Missing 5 7  5 4  
Other NSAID use, %       
   Yes  6 7 0.4 10 12 0.4 
   No  94 93  90 88  
Statin use, %       
   Yes  14 34 <0.01 16 18 0.6 
   No  86 66  84 82  
Type II diabetes, %       
   Yes  2 2 1.0 3 0 0.05 
   No  98 98  98 100  
Cardiovascular disease, %       
   Yes  1 24 <0.01 4 1 0.2 
   No  99 76  96 99  
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Arthritis, %       
   Yes  2 4 0.05 1 19 <0.01 
   No  98 96  99 81  
PSA, prostate-specific antigen; BMI, body mass index; PCa, prostate cancer; NA-NSAID, non-aspirin nonsteroidal 
anti-inflammatory drug   
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Table 3-2. Aspirin and NA-NSAID use at the time of the preoperative consultation and 
prostate cancer recurrence, Johns Hopkins Hospital Radical Prostatectomy Cohort 
 









Aspirin Use      
   No 265 / 23136 1.00 -- 1.00 -- 
   Yes 35 / 2486 1.14 (0.80, 1.62) 1.16 (0.79, 1.69) 
NA-NSAID Use      
   No 278 / 24305 1.00 -- 1.00 -- 
   Yes 22 / 1317 1.37 (0.89, 2.11) 1.06 (0.64, 1.75) 
NA-NSAID, non-aspirin nonsteroidal anti-inflammatory drug* 
Adjusted for age, stage (<T3, ≥T3), grade (<4+3, ≥4+3), year of surgery, race (white, non-white), BMI at the time of 
surgery (<25, 25-30, ≥30 kg/m2, missing), use of statins at the time of surgery, cardiovascular disease, arthritis 
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Table 3-3. Aspirin and NA-NSAID use at the time of the preoperative consultation and prostate cancer recurrence, stratified 
by stage & grade at surgery and year of surgery, Johns Hopkins Hospital Radical Prostatectomy Cohort 
 
 Low Stage & Low Grade High Stage or High Grade 








HR 95% CI HR 95% CI 
Events/ 
Person-years 
HR 95% CI HR 95% CI 
Aspirin Use 
   No 4 / 16722 1.00 -- 1.00 -- 220 / 6414 1.00 -- 1.00 -- 
   Yes 3 / 1713 0.64 (0.20, 2.07) 0.61 (0.17, 2.20) 32 / 773 1.14 (0.78, 1.65) 1.23 (0.82, 1.83) 
NA-NSAID Use 
   No 43 / 17550 1.00 -- 1.00 -- 235 / 6755 1.00 -- 1.00 -- 
   Yes 5 / 885 2.31 (0.92, 5.85) 2.35 (0.86, 6.42) 17 / 432 1.01 (0.62, 1.66) 0.89 (0.50, 1.58) 
             
 Year of Surgery <2000 Year of Surgery ≥2000 









HR 95% CI HR 95% CI 
Events/ 
Person-years 
HR 95% CI HR 95% CI 
Aspirin Use 
   No 186 / 14752 1.00 -- 1.00 -- 79 / 8384 1.00 -- 1.00 -- 
   Yes 23 / 1644 1.05 (0.68, 1.62) 1.11 (0.69, 1.78) 12 / 842 1.33 (0.72, 2.46) 1.32 (0.69, 2.51) 
NA-NSAID Use 
   No 194 / 15712 1.00 -- 1.00 -- 84 / 8593 1.00 -- 1.00 -- 
   Yes 15 / 684 1.69 (1.00, 2.86) 1.35 (0.72, 2.52) 7 / 633 1.08 (0.50, 2.33) 0.68 (0.29, 1.58) 
NA-NSAID, non-aspirin nonsteroidal anti-inflammatory drug 
*Adjusted for age, year of surgery, race (white, non-white), BMI at the time of surgery (<25, 25-30, ≥30, missing), use of statins at the time of surgery, 
cardiovascular disease, arthritis  
**Adjusted for age, stage (<T3, ≥T3), grade (<4+3, ≥4+3), year of surgery, race (white, non-white), BMI at the time of surgery (<25, 25-30, ≥30 kg/m2, missing), use 
of statins at the time of surgery, cardiovascular disease, arthritis
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Table 3-4. Aspirin and NA-NSAID use at the time of the preoperative consultation and 
prostate cancer metastases, Johns Hopkins Hospital Radical Prostatectomy Cohort 
 









Aspirin Use      
   No 70 / 23540 1.00 -- 1.00 -- 
   Yes 11 / 2574 1.28 (0.68, 2.43) 1.00 (0.48, 2.07) 
NA-NSAID Use      
   No 75 / 24772 1.00 -- 1.00 -- 
   Yes 6 / 1342 1.44 (0.63, 3.32) 1.16 (0.48, 2.79) 
NA-NSAID, non-aspirin nonsteroidal anti-inflammatory drug 
*Adjusted for age, stage (<T3, ≥T3), grade (<4+3, ≥4+3), year of surgery, race (white, non-white), BMI at the time of 




Table 3-5. Comparison of men who did and did not complete the mailed survey in 2007, 
Johns Hopkins Hospital Radical Prostatectomy Cohort 
  





N 859 1505  
Age, years, mean 55.7 56.6 <0.01 
Year of surgery, mean  1998.6 1999.3 <0.01 
PSA value, ng/mL, mean  7.43 6.59 <0.01 
Pathologic stage, %    
   <T3  67 74 <0.01 
   ≥T3 33 26  
Pathologic grade (Gleason 
sum), % 
   
   <4+3 89 90 0.2 
   ≥4+3 11 10  
Race, %    
   White 89 95 <0.01 
   Black 4 2  
   Other/Missing 7 3  
BMI, %    
   <25 kg/m2 30 34 0.1 
   25 - <30 kg/m2 53 53  
   ≥30kg/m2 12 10  
   Missing 5 4  
Family history of PCa, %    
   Yes 35 38 0.06 
   No 59 57  
   Missing 6 5  
Aspirin use at Sx, %    
   Yes 9 10 0.2 
   No 91 90  
NA-NSAID use at Sx, %    
   Yes 5 6 0.5 
   No 95 94  
Statin use at Sx, %    
   Yes 15 17 0.1 
   No 85 83  
Type II diabetes, %    
   Yes 3 2 0.4 
   No 97 98  
Cardiovascular disease, %     
   Yes 5 3 0.04 
   No 95 97  
Arthritis, %    
   Yes 3 2 0.9 
   No 98 98  
PSA, prostate-specific antigen; BMI, body mass index; PCa, prostate cancer; Sx, Surgery; NA-NSAID, non-aspirin 
nonsteroidal anti-inflammatory drug  
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Table 3-6. Age-adjusted baseline characteristics of men who completed the survey, by 
aspirin and NA-NSAID use pre-surgery*, Johns Hopkins Hospital Radical Prostatectomy 
Cohort 
 
 Aspirin Use NA-NSAID Use 
  No Yes p-value No Yes p-value 
N  841 604  1082 353  
Age, years, mean 55.8 57.9 <0.01 56.9 56.0 0.03 
Year of surgery, mean  1999.1 1999.7 <0.01 1999.2 1999.7 0.03 
PSA value, ng/mL, mean  6.7 6.3 0.09 6.6 6.1 0.06 
Pathologic stage, %       
   <T3  76 75 0.7 75 75 1.0 
   ≥T3 24 25  25 25  
Pathologic grade (Gleason 
sum), % 
      
   <4+3  91 92 0.6 91 91 0.8 
   ≥4+3  9 8  9 9  
Race, %       
   White  94 95 0.9 94 96 0.1 
   Black  2 1  2 1  
   Other/Missing 3 4  4 2  
BMI, %       
   <25 kg/m2  38 35 0.2 37 35 0.4 
   25 - <30 kg/m2  51 53  52 52  
   ≥30 kg/m2  8 9  8 10  
   Missing 2 3  2 2  
Weight change >2.2 kg**, 
% 
      
   Yes 29 26 0.7 27 28 0.9 
   No 69 71  70 70  
   Missing 2 3  2 2  
Smoking status 1-year 
post-surgery, % 
      
   Never 54 52 0.9 54 49 0.3 
   Former 43 47  43 49  
   Current 2 1  2 2  
   Missing 1 1  1 0  
Family history of PCa, %       
   Yes  38 34 0.1 37 35 0.5 
   No  57 62  58 60  
   Missing 5 4  5 4  
Other NSAID use pre-
surgery, % 
      
   Yes  17 34 <0.01 36 58 <0.01 
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   No  83 64  64 41  
   Missing 0 2  0 0  
Statin use pre-surgery, %       
   Yes  15 36 <0.01 23 25 0.2 
   No  85 64  77 74  
   Missing 0 1  0 1  
Type II diabetes, %       
   Yes  1 3 <0.01 2 3 0.3 
   No  99 97  98 97  
Cardiovascular disease, %       
   Yes  1 6 <0.01 3 3 0.8 
   No  99 94  97 97  
Arthritis, %       
   Yes  3 1 0.02 2 4 <0.01 
   No  97 99     
*Excludes men with who experienced the event of interest or who were lost to follow-up within one year of surgery, 
and men missing data on aspirin and NA-NSAID use pre-surgery 




Table 3-7. Aspirin use pre- and post-surgery and prostate cancer recurrence among men 
who completed the 2007 survey, with time at risk beginning one-year post-surgery, 
Johns Hopkins Hospital Radical Prostatectomy Cohort 
 










Aspirin Use Pre-Surgery 
Ever Use 
     
   No 78 / 9563 1.00 -- 1.00 -- 
   Yes 69 / 6619 1.19 (0.86, 1.65) 1.29 (0.91, 1.82) 
Duration of Use 
     
   <1 year 78 / 9770 1.00 -- 1.00 -- 
   1-4 years 15 / 1487 1.18 (0.68, 2.06) 1.45 (0.82, 2.56) 
   5-9 years 21 / 1557 1.53 (0.94, 2.49) 1.28 (0.77, 2.12) 
   ≥10 years 31 / 3179 1.15 (0.76, 1.75) 1.27 (0.82, 1.96) 
Aspirin Use Post-Surgery 
Ever Use 
     
   No 57 / 7070 1.00 -- 1.00 -- 
   Yes 90 / 9032 1.16 (0.83, 1.63) 1.37 (0.96, 1.96) 
Aspirin Use Pre- & Post-Surgery 
Ever Use 
     
   Never 52 / 6464 1.00 -- 1.00 -- 
   Pre- Only 5 / 582 1.00 (0.40, 2.50) 0.75 (0.30, 1.90) 
   Post- Only 25 / 3020 1.00 (0.62, 1.61) 1.09 (0.66, 1.78) 
   Pre- and Post- 64 / 5941 1.23 (0.85, 1.79) 1.47 (0.99, 2.19) 
*Adjusted for age, stage (<T3, ≥T3), grade (<4+3, ≥4+3), year of surgery, race (white, non-white), smoking status 
one-year after surgery, BMI one-year after surgery (<25, 25-30, ≥30 kg/m2), weight change >2.2kg, ever use of 
statins pre-surgery, cardiovascular disease, and arthritis 
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Table 3-8. Aspirin use pre- and post-surgery and prostate cancer recurrence among men who completed the 2007 survey, 
with time at risk beginning one-year post-surgery, stratified by stage & grade and year of surgery, Johns Hopkins Hospital 
Radical Prostatectomy Cohort 
 
 Low Stage & Low Grade High Stage or High Grade 








HR 95% CI HR 95% CI 
Events/ 
Person-years 
HR 95% CI HR 95% CI 
Aspirin Use Pre-Surgery 
   No 17 / 7097 1.00 -- 1.00 -- 61 / 2466 1.00 -- 1.00 -- 
   Yes 14 / 4851 1.20 (0.59, 2.46) 1.40 (0.66, 2.98) 55 / 1768 1.21 (0.84, 1.75) 1.33 (0.89, 1.97) 
Aspirin Use Post-Surgery 
   No 11 / 5203 1.00 -- 1.00 -- 46 / 1867 1.00 -- 1.00 -- 
   Yes 21 / 6646 1.48 (0.71, 3.11) 1.52 (0.71, 3.24) 69 / 2386 1.17 (0.80, 1.70) 1.37 (0.92, 2.06) 
             
 Year of Surgery <2000 Year of Surgery ≥2000 









HR 95% CI HR 95% CI 
Events/ 
Person-years 
HR 95% CI HR 95% CI 
Aspirin Use Pre-Surgery 
   No 62 / 6296 1.00 -- 1.00 -- 16 / 3267 1.00 -- 1.00 -- 
   Yes 42 / 3972 1.02 (0.69, 1.51) 1.04 (0.68, 1.59) 27 / 2647 1.97 (1.05, 3.70) 2.39 (1.20, 4.77) 
Aspirin Use Post-Surgery 
No 41 / 4340 1.00 -- 1.00 -- 16 / 2730 1.00 -- 1.00 -- 
Yes 63 / 5878 1.07 (0.72, 1.58) 1.18 (0.79, 1.79) 27 / 3154 1.38 (0.74, 2.59) 2.02 (0.99, 4.11) 
*Adjusted for age, year of surgery, race (white, non-white), smoking status one-year after surgery, BMI one-year after surgery (<25, 25-30, ≥30 kg/m2), weight 
change >2.2 kg, ever use of statins pre-surgery, cardiovascular disease, and arthritis 
**Adjusted for age, stage (<T3, ≥T3), grade (<4+3, ≥4+3), year of surgery, race (white, non-white), smoking status one-year after surgery, BMI one-year after 
surgery (<25, 25-30, ≥30 kg/m2), weight change >2.2 kg, ever use of statins pre-surgery, cardiovascular disease, and arthritis 
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Table 3-9. NA-NSAID use pre- and post-surgery and prostate cancer recurrence among 
men who completed the 2007 survey, with time at risk beginning one-year post-surgery, 
Johns Hopkins Hospital Radical Prostatectomy Cohort 
 










NA-NSAID Use Pre-Surgery 
Ever Use 
     
   No 115 / 12246 1.00 -- 1.00 -- 
   Yes 30 / 3829 0.85 (0.57, 1.26) 0.96 (0.64, 1.45) 
Duration of Use 
     
   <1 year 118 / 12520 1.00 -- 1.00 -- 
   1-4 years 4 / 833 0.50 (0.19, 1.36) 0.72 (0.24, 2.13) 
   5-9 years 4 / 87 0.50 (0.18, 1.35) 0.57 (0.21, 1.55) 
   ≥10 years 17 / 1653 1.16 (0.69, 1.93) 1.14 (0.70, 1.92) 
NA-NSAID Use Post-Surgery 
Ever Use 
     
   No 97 / 11456 1.00 -- 1.00 -- 
   Yes 47 / 4561 1.23 (0.87, 1.75) 1.20 (0.84, 1.71) 
NA-NSAID Use Pre- & Post-Surgery 
Ever Use 
     
   Never 96 / 10733 1.00 -- 1.00 -- 
   Pre- Only 1 / 653 ** ** ** ** 
   Post- Only 18 / 1388 1.50 (0.91, 2.49) 1.08 (0.64, 1.81) 
   Pre- and Post- 29 / 3121 1.04 (0.69, 1.58) 1.23 (0.80, 1.88) 
NA-NSAID, non-aspirin nonsteroidal anti-inflammatory drug 
*Adjusted for age, stage (<T3, ≥T3), grade (<4+3, ≥4+3), year of surgery, race (white, non-white), smoking status 
one-year after surgery, BMI one-year after surgery (<25, 25-30, ≥30 kg/m2), weight change >2.2 kg, ever use of 
statins pre-surgery, cardiovascular disease, and arthritis 
**Not enough events to calculate stable HRs and 95% CIs 
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Table 3-10. NA-NSAID use pre- and post-surgery and prostate cancer recurrence among men who completed the 2007 
survey, with time at risk beginning one-year post-surgery, stratified by stage & grade and year of surgery, Johns Hopkins 
Hospital Radical Prostatectomy Cohort 
 
 Low Stage & Low Grade High Stage or High Grade 








HR 95% CI HR 95% CI 
Events/ 
Person-years 
HR 95% CI HR 95% CI 
NA-NSAID Use Pre-Surgery 
   No 24 / 9032 1.00 -- 1.00 -- 91 / 3214 1.00 -- 1.00 -- 
   Yes 7 / 2832 0.92 (0.40, 2.14) 0.97 (0.42, 2.27) 23 / 997 0.82 (0.52, 1.29) 0.91 (0.57, 1.48) 
NA-NSAID Use Post-Surgery 
   No 20 / 8509 1.00 -- 1.00 -- 77 / 2947 1.00 -- 1.00 -- 
   Yes 11 / 3281 1.42 (0.68, 2.97) 1.40 (0.67, 2.94) 36 / 1280 1.09 (0.73, 1.63) 1.13 (0.75, 1.70) 
             
 Year of Surgery <2000 Year of Surgery ≥2000 









HR 95% CI HR 95% CI 
Events/ 
Person-years 
HR 95% CI HR 95% CI 
NA-NSAID Use Pre-Surgery 
   No 80 / 7917 1.00 -- 1.00 -- 35 / 4329 1.00 -- 1.00 -- 
   Yes 22 / 2270 0.97 (0.61, 1.56) 1.07 (0.66, 1.74) 8 / 1559 0.65 (0.30, 1.40) 0.61 (0.26, 1.42) 
NA-NSAID Use Post-Surgery 
   No 67 / 7299 1.00 -- 1.00 -- 30 / 4157 1.00 -- 1.00 -- 
   Yes 35 / 2872 1.35 (0.90, 2.03) 1.42 (0.93, 2.18) 12 / 1689 0.99 (0.51, 1.94) 0.62 (0.31, 1.27) 
NA-NSAID, non-aspirin nonsteroidal anti-inflammatory drug 
*Adjusted for age, year of surgery, race (white, non-white), smoking status one-year after surgery, BMI one-year after surgery (<25, 25-30, ≥30 kg/m2), weight 
change >2.2 kg, ever use of statins pre-surgery, cardiovascular disease, and arthritis 
**Adjusted for age, stage (<T3, ≥T3), grade (<4+3, ≥4+3), year of surgery, race (white, non-white), smoking status one-year after surgery, BMI one-year after 
surgery (<25, 25-30, ≥30 kg/m2), weight change >2.2 kg, ever use of statins pre-surgery, cardiovascular disease, and arthritis 
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Table 3-11. Aspirin and NA-NSAID use pre- and post-surgery and prostate cancer 
metastases among men who completed the 2007 survey, with time at risk beginning one-
year post-surgery, Johns Hopkins Hospital Radical Prostatectomy Cohort 
 









Aspirin Use Pre-Surgery     
   No 24 / 9717 1.00 -- 1.00 -- 
   Yes 20 / 6574 1.12 (0.60, 2.10) 0.89 (0.43, 1.82) 
Aspirin Use Post-Surgery     
   No 18 / 7009 1.00 -- 1.00 -- 
   Yes 25 / 9199 0.97 (0.51, 1.84) 1.17 (0.56, 2.43) 
NA-NSAID Use Pre-Surgery     
   No 34 / 12462 1.00 -- 1.00 -- 
   Yes 8 / 3701 0.81 (0.35, 1.83) 0.73 (0.30, 1.77) 
NA-NSAID Use Post-Surgery     
   No 32 / 11461 1.00 -- 1.00 -- 
   Yes 10 / 4657 0.79 (0.37, 1.66) 0.65 (0.30, 1.41) 
NA-NSAID, non-aspirin nonsteroidal anti-inflammatory drug 
*Adjusted for age, stage (<T3, ≥T3), grade (<4+3, ≥4+3), year of surgery, race (white, non-white), BMI at the time of 




Table 3-12. Age-adjusted baseline characteristics of men who completed the survey and 
were still at risk for recurrence in 2007, by aspirin and NA-NSAID use pre-surgery, Johns 
Hopkins Hospital Radical Prostatectomy Cohort 
 
 Aspirin Use NA-NSAID Use 
  No Yes p-value No Yes p-value 
N  774 552  994 324  
Age, years, mean 55.7 57.8 <0.01 56.8 56.0 0.05 
Year of surgery, mean  1999.3 1999.9 0.01 1999.4 1999.9 0.04 
PSA value, ng/mL, mean  6.5 6.1 0.06 6.4 6.0 0.09 
Pathologic stage, %       
   <T3  79 79 0.9 79 78 0.8 
   ≥T3 21 21  21 22  
Pathologic grade 
(Gleason sum), % 
      
   <4+3  93 94 0.5 93 93 0.9 
   ≥4+3  7 6  7 7  
Race, %       
   White  94 95 0.7 94 97 0.08 
   Black  2 1  2 1  
   Other/Missing 4 4  4 2  
BMI, %       
   <25 kg/m2  38 34 0.1 37 35 0.4 
   25 - <30 kg/m2  52 54  53 53  
   ≥30 kg/m2  7 9  7 10  
   Missing 2 2  2 2  
Weight change >2.2 kg*, 
% 
      
   Yes 28 26 0.6 27 28 0.9 
   No 70 72  70 70  
   Missing 2 3  2 2  
Smoking status 1-year 
post-surgery, % 
      
   Never 54 52 0.7 55 51 0.4 
   Former 42 46  43 47  
   Current 2 1  2 2  
   Missing 1 1  1 0  
Family history of PCa, %       
   Yes  39 34 0.08 37 35 0.3 
   No  57 62  58 61  
   Missing 5 4  5 4  
Other NSAID use pre-
surgery, % 
      
   Yes  18 33 <0.01 36 57 <0.01 
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   No  82 65  64 43  
   Missing 0 2  0 0  
Statin use pre-surgery, %       
   Yes  16 37 <0.01 24 26 0.2 
   No  84 63  76 73  
   Missing 0 1  0 1  
Type II diabetes, %       
   Yes  1 3 0.01 2 3 0.6 
   No  99 97  98 97  
Cardiovascular disease, 
% 
      
   Yes  1 6 <0.01 3 3 0.7 
   No  99 94  97 97  
Arthritis, %       
   Yes  3 1 0.04 2 5 <0.01 
   No  97 99  98 95  
PSA, prostate-specific antigen; BMI, body mass index; PCa, prostate cancer; NA-NSAID, non-aspirin nonsteroidal 
anti-inflammatory drug 




Table 3-13. Aspirin use pre- and post-surgery and prostate cancer recurrence among 
men who completed the 2007 survey, with time at risk beginning in 2007, Johns Hopkins 
Hospital Radical Prostatectomy Cohort 
 










Aspirin Use Pre-Surgery 
Ever Use 
     
   No 25 / 4157 1.00 -- 1.00 -- 
   Yes 31 / 2971 1.67 (0.98, 2.85) 2.05 (1.13, 3.72) 
Duration of Use 
     
   <1 year 25 / 4248 1.00 -- 1.00 -- 
   1-4 years 7 / 722 1.60 (0.69, 3.70) 2.27 (0.93, 5.56) 
   5-9 years 10 / 682 2.38 (1.14, 4.99) 2.00 (0.92, 4.34) 
   ≥10 years 13 / 1379 1.55 (0.79, 3.04) 2.09 (0.99, 4.40) 
Aspirin Use Post-Surgery 
Ever Use 
     
   No 18 / 3189 1.00 -- 1.00 -- 
   Yes 39 / 3908 1.69 (0.96, 2.97) 2.22 (1.18, 4.16) 
Aspirin Use Pre- & Post-Surgery 
Ever Use 
     
   Never 17 / 2922 1.00 -- 1.00 -- 
   Pre- Only 1 / 256 ** ** ** ** 
   Post- Only 8 / 1203 1.11 (0.48, 2.57) 1.44 (0.59, 3.53) 
   Pre- and Post- 30 / 2677 1.84 (1.01, 3.36) 2.61 (1.31, 5.19) 
*Adjusted for age, stage (<T3, ≥T3), grade (<4+3, ≥4+3), year of surgery, race (white, non-white), smoking status 
one-year after surgery, BMI one-year after surgery (<25, 25-30, ≥30 kg/m2), weight change >2.2 kg, ever use of 
statins pre-surgery, cardiovascular disease, and arthritis 




Table 3-14. Aspirin use pre- and post-surgery and prostate cancer recurrence among men who completed the 2007 survey, 
with time at risk beginning in 2007, stratified by stage & grade and year of surgery, Johns Hopkins Hospital Radical 
Prostatectomy Cohort 
 
 Low Stage & Low Grade High Stage or High Grade 








HR 95% CI HR 95% CI 
Events/ 
Person-years 
HR 95% CI HR 95% CI 
Aspirin Use Pre-Surgery 
   No 5 / 3214 1.00 -- 1.00 -- 20 / 943 1.00 -- 1.00 -- 
   Yes 8 / 2303 2.15 (0.70, 6.65) 2.54 (0.77, 8.37) 23 / 668 1.64 (0.90, 3.00) 1.91 (0.97, 3.78) 
Aspirin Use Post-Surgery 
   No 3 / 2435 1.00 -- 1.00 -- 15 / 754 1.00 -- 1.00 -- 




28 / 873 1.65 (0.87, 3.11) 1.92 (0.95, 3.87) 
             
 Year of Surgery <2000 Year of Surgery ≥2000 









HR 95% CI HR 95% CI 
Events/ 
Person-years 
HR 95% CI HR 95% CI 
Aspirin Use Pre-Surgery 
   No 14 / 2146 1.00 -- 1.00 -- 11 / 2011 1.00 -- 1.00 -- 
   Yes 12 / 1336 1.33 (0.61, 2.88) 1.55 (0.67, 3.57) 19 / 1635 2.07 (0.97, 4.40) 3.08 (1.31, 7.26) 
Aspirin Use Post-Surgery 
   No 8 / 1473 1.00 -- 1.00 -- 10 / 1716 1.00 -- 1.00 -- 
   Yes 19 / 1998 1.67 (0.73, 3.84) 1.75 (0.74, 4.18) 20 / 1911 1.73 (0.80, 3.73) 2.47 (1.02, 6.01) 
*Adjusted for age, year of surgery, race (white, non-white), smoking status one-year after surgery, BMI one-year after surgery (<25, 25-30, ≥30 kg/m2), weight 
change >2.2 kg, ever use of statins pre-surgery, cardiovascular disease, and arthritis 
**Adjusted for age, stage (<T3, ≥T3), grade (<4+3, ≥4+3), year of surgery, race (white, non-white), smoking status one-year after surgery, BMI one-year after 
surgery (<25, 25-30, ≥30 kg/m2), weight change >2.2 kg, ever use of statins pre-surgery, cardiovascular disease, and arthritis 
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Table 3-15. NA-NSAID use pre- and post-surgery and prostate cancer recurrence among 
men who completed the 2007 survey, with time at risk beginning in 2007, Johns Hopkins 
Hospital Radical Prostatectomy Cohort 
 










NA-NSAID Use Pre-Surgery 
Ever Use 
     
   No 45 / 5335 1.00 -- 1.00 -- 
   Yes 11 / 1748 0.76 (0.39, 1.48) 0.92 (0.46, 1.82) 
Duration of Use 
     
   <1 year 45 / 5446 1.00 -- 1.00 -- 
   1-4 years 0 / 390 ** ** ** ** 
   5-9 years 2 / 397 ** ** ** ** 
   ≥10 years 9 / 750 1.53 (0.75, 3.13) 1.63 (0.78, 3.41) 
NA-NSAID Use Post-Surgery 
Ever Use 
     
   No 38 / 5082 1.00 -- 1.00 -- 
   Yes 17 / 1971 1.16 (0.65, 2.05) 1.19 (0.66, 2.15) 
NA-NSAID Use Pre- & Post-Surgery 
Ever Use 
     
   Never 37 / 4743 1.00 -- 1.00 -- 
   Pre- Only 1 / 311 ** ** ** ** 
   Post- Only 7 / 535 1.65 (0.74, 3.70) 1.15 (0.50, 2.67) 
   Pre- and Post- 10 / 1413 0.92 (0.46, 1.85) 1.16 (0.56, 2.41) 
NA-NSAID, non-aspirin nonsteroidal anti-inflammatory drug 
*Adjusted for age, stage (<T3, ≥T3), grade (<4+3, ≥4+3), year of surgery, race (white, non-white), smoking status 
one-year after surgery, BMI one-year after surgery (<25, 25-30, ≥30 kg/m2), weight change >2.2 kg, ever use of 
statins pre-surgery, cardiovascular disease, and arthritis 
**Not enough events to calculate stable HRs and 95% CIs
102 
 
Appendix 3-1. Methods to explore and control for selection bias 
 
 In the analyses utilizing data from the 2007 survey, there was potential for selection bias 
due to the fact that only men who completed the survey (64% of the original cohort) were 
included. Men excluded from the analyses included those who died from prostate cancer prior to 
2007 (n=22), those who died from other causes prior to 2007 (n=51), those who were lost to 
follow-up prior to 2007 (n=218), and those who were either mailed the survey and did not 
respond, or who were not mailed the survey due to residency outside of the U.S. (n=568). 
Exclusion of these men from the analysis could have led to selection bias if selection was 
associated with both NSAID use and prostate cancer recurrence, either via direct relationships 
or common causes, or if the association between selection and recurrence differed by level of 
NSAID use (96, 97). 
 We were fortunate to have data on the men who did not complete the 2007 survey, 
allowing us to explore potential for selection bias. We compared characteristics of men who 
completed vs. did not complete the survey in Table 3-5. Aspirin and NA-NSAID use at the time 
of the preoperative consultation did not differ significantly by survey completion, but the 
percentage of reported aspirin and NA-NSAID was low, and minor differences between survey 
non-responders and responders (9 vs. 10% for aspirin, 5 vs. 6% for NA-NSAIDs) may have still 
been meaningful. Survey completion was strongly associated with prostate cancer recurrence, 
even after adjusting for age, race, and pathologic stage (HR: 1.53, 95% CI: 1.21-1.93). The 
association between selection and recurrence also appeared to vary by level of aspirin use ( 
Supplemental Figure 3-1), suggesting that selection bias was possible.  
To account for possible selection bias, as a sensitivity analysis, models using the 2007 
survey data were re-run using inverse probability of selection weights (IPSW). Predicted 
probabilities of selection were calculated from a logistic regression model in which survey 
completion was regressed onto the following covariates: age, year of surgery, age*year of 
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surgery, race, ethnicity, BMI, family history of prostate cancer, pathologic stage, pathologic 
Gleason, diagnostic PSA value, medications used at the time of the preoperative consultation 
(including aspirin, NA-NSAIDs, statins, angiotensin-converting enzyme inhibitors, beta blockers, 
diuretics, hypertension medications, CVD medications, asthma medications, gastroesophageal 
reflux disease medications, gout medications, diabetes medications, insulin, and psychiatric 
medications), comorbidities (CVD, arthritis, hypertension, type II diabetes, other cancers), 
age*CVD, and year of surgery*CVD. Weights were constructed from the inverse of the predicted 
probabilities and stabilized using the marginal probability of selection. The weights were then 
incorporated into Cox proportional hazards regression with robust variance estimation.  
As shown in Supplemental Table 3-1, when models were weighted using IPSW, results were 
very similar to those from the primary analyses presented in Table 3-7 and Table 3-9. This 
suggests that our results may not have been heavily influenced by selection bias. Alternatively, 
this could suggest that our model for selection did not sufficiently discriminate between men 
who did and did not complete the survey (AUC: 0.63) or that the IPSW did not block all 
backdoor pathways induced by selection. The varying reasons for selection (i.e. death, change 
of residence out of the U.S., or non-response) made it difficult to model the probability of 







Supplemental Figure 3-1. Association between survey completion and prostate cancer 
recurrence, by level of aspirin use at the preoperative consultation 





Supplemental Table 3-1. Aspirin and NA-NSAID use pre- and post-surgery and prostate 
cancer recurrence among men who completed the 2007 survey, with time at risk 
beginning one-year post-surgery and models weighted using inverse probability of 
selection weights, Johns Hopkins Hospital Radical Prostatectomy Cohort 
 










Aspirin Use Pre-Surgery 
   No 78 / 9563 1.00 -- 1.00 -- 
   Yes 69 / 6619 1.14 (0.82, 1.58) 1.26 (0.89, 1.78) 
Aspirin Use Post-Surgery 
   No 57 / 7070 1.00 -- 1.00 -- 
   Yes 90 / 9032 1.13 (0.81, 1.59) 1.33 (0.92, 1.94) 
NA-NSAID Use Pre-Surgery 
   No 115 / 12246 1.00 -- 1.00 -- 
   Yes 30 / 3829 0.86 (0.58, 1.29) 1.02 (0.68, 1.52) 
NA-NSAID Use Post-Surgery 
   No 97 / 11456 1.00 -- 1.00 -- 
   Yes 47 / 4561 1.26 (0.89, 1.78) 1.29 (0.91, 1.82) 
NA-NSAID, non-aspirin nonsteroidal anti-inflammatory drug 
*Adjusted for age, stage (<T3, ≥T3), grade (<4+3, ≥4+3), year of surgery, race (white, non-white), smoking status 
one-year after surgery, BMI one-year after surgery (<25, 25-30, ≥30 kg/m2), weight change >2.2 kg, ever use of 





Chapter 4. Aspirin Use and Inflammation and Immune 









Background: Regular aspirin use is inversely associated with prostate cancer risk in meta-
analyses of observational studies, and is hypothesized to act by reducing inflammation within 
the prostate. However, a direct link between aspirin use and intraprostatic inflammation has not 
been established. This study investigated the association between aspirin use and the presence 
and extent of intraprostatic inflammation, and the abundance of specific immune cell types, in 
benign prostate tissue of men from the placebo arm of the Prostate Cancer Prevention Trial 
(PCPT). 
Methods: This cross-sectional study included a subset of men from the placebo arm of PCPT, 
sampled for a previous case-control study of inflammation and lower urinary tract symptoms 
(LUTS). Aspirin use was ascertained at trial entry (1993-1997). The presence and extent of 
inflammation was assessed, and markers of specific immune cell types (CD4, CD8, FoxP3, 
CD68, c-KIT) were scored, in slides from end-of-study prostate biopsies seven years later. 
Logistic regression was used to estimate associations between aspirin use and each outcome, 
adjusted for potential confounders.  
Results: There were 357 men included in this study. Forty-three percent reported aspirin use at 
trial entry. The prevalence of intraprostatic inflammation was similar for aspirin users and non-
users (66% vs. 67%, respectively), but aspirin users were less likely to have inflammation in all 
of their biopsy cores (OR: 0.31, 95% CI: 0.11-0.91). Using the median score as the reference, 
aspirin users were also more likely to exhibit low levels of FoxP3, a marker of T regulatory cells 
(Tregs) (OR: 3.39, 95% CI: 1.06-10.91). Other immune cell types did not markedly differ in 
prostate tissue of aspirin users and non-users. Similar results were observed when analyses 
were restricted to LUTS controls (N=86), men without prostate cancer detected at the end-of-
study biopsy (N=295), and men with a PSA <4 ng/mL prior to the end-of-study biopsy (N=317).  
108 
 
Conclusions: In this study, aspirin use was inversely associated with the extent of inflammation 
and the abundance of Tregs within the prostate. This study provides suggestive evidence that 







A growing body of evidence supports that chronic inflammation contributes to prostate 
carcinogenesis (29). Intraprostatic inflammation is highly prevalent in older men with elevated 
prostate-specific antigen (PSA), abnormal digital-rectal examination (DRE), or benign prostatic 
hyperplasia (98-100), and in older men without prostate symptoms (101-103). Chronic 
inflammation in the prostate could arise through exposure to infectious agents, environmental 
toxins, dietary factors, or hormones, and could contribute to carcinogenesis via release of 
mutagenic reactive oxygen species or pro-proliferative and angiogenic cytokines (29).  
Despite biological plausibility, establishing a direct epidemiologic link between chronic 
intraprostatic inflammation and prostate cancer has been challenging, in part due to the difficulty 
of measuring inflammation in benign prostate tissue. Inflammation can be assessed in tissue 
collected for clinical indication (i.e. elevated PSA, an indicator of possible prostate cancer), but 
intraprostatic inflammation may also contribute to rising PSA levels (65). As a result, tissue 
collected for indication is enriched for inflammation, regardless of prostate cancer status. Of the 
few studies that have examined inflammation in men without indication for biopsy, one case-
control study reported a positive association between inflammation in at least biopsy core and 
overall and high-grade prostate cancer (102), while a prospective study reported a positive trend 
between increasing mean percentage area of tissue with inflammation and odds of subsequent 
prostate cancer diagnosis (103). 
If intraprostatic inflammation is causally associated with prostate cancer, then 
interventions to decrease inflammation, such as use of aspirin or other nonsteroidal anti-
inflammatory drugs (NSAIDs), could plausibly reduce prostate cancer risk. In fact, regular use of 
aspirin and other non-aspirin NSAIDs are inversely associated with prostate cancer risk 
according to meta-analyses of observational studies (41, 42). Evidence of a relationship 
between NSAID use and intraprostatic inflammation would enhance the biological plausibility of 
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these findings; however, to our knowledge, this association has not yet been examined in 
prostate tissue collected without clinical indication. 
The purpose of this study was to investigate the association between aspirin use and the 
prevalence and extent of inflammation, as well as the abundance of specific immune cell types, 
in benign prostate tissue collected without indication from men in the placebo arm of the 
Prostate Cancer Prevention Trial (PCPT). We hypothesized that aspirin use would be 
associated with a decreased prevalence and extent of intraprostatic inflammation and a differing 




This study included men from the Prostate Cancer Prevention Trial (PCPT), a phase III, 
randomized, double-blinded, placebo-controlled trial designed to evaluate finasteride for the 
primary prevention of prostate cancer (104). Between 1993 and 1997, the trial recruited 18,882 
men ages 55 years and older with no evidence of prostate cancer at enrollment (normal DRE, 
PSA ≤3 ng/mL, and International Prostate Symptom Score (IPSS) <20) from 221 study sites 
across the U.S. Participants underwent annual prostate cancer screening for up to seven years 
and were recommended for biopsy if their PSA was ≥4 ng/mL or their DRE was abnormal. At 
the end of seven years, all participants not diagnosed with prostate cancer were asked to 
undergo an end-of-study biopsy, irrespective of indication. 
The current study included men from the placebo arm of PCPT who underwent an end-
of-study biopsy and were selected for a nested case-control study of lower urinary tract 
symptoms (LUTS) incidence and progression (101). Case-control sets for LUTS incidence and 
progression were developed based on the IPSS at baseline and seven years. Participants who 
had prostate cancer detected at the end-of-study biopsy were not excluded, to minimize 
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potential for selection bias. For the current study, LUTS cases and controls were combined, as 
LUTS case-control status was only weakly associated with intraprostatic inflammation in the 
prior study (101). 
PCPT was approved by institutional review boards (IRBs) at all participating study sites; 
the current study was approved by the Johns Hopkins Bloomberg School of Public Health IRB 
and the Colorado Multiple IRBs. 
 
Measurement of Aspirin Use and Other Covariates 
At enrollment, baseline demographics, medical, and lifestyle factors were collected via 
questionnaire. Current medication use was assessed with both closed (i.e. “Do you use 
aspirin?”) and open-ended questions, and responses were used to categorize individuals as 
aspirin users or non-users at trial entry. Baseline weight and height were measured using 
standardized protocols, and weight was re-measured annually. From these measurements, 
body mass index (BMI) was calculated as weight (kg) divided by the square of height (m2). Men 
were asked to complete a food frequency questionnaire at the first annual follow-up, and serum 
PSA was measured in samples collected from baseline and annual follow-ups at a central 
laboratory. 
 
Measurement of Intraprostatic Inflammation and Immune Cell Markers 
This study used data previously collected for the LUTS nested case-control study (101). 
Briefly, to assess presence and extent of inflammation, an average of 2 (range: 1-6) randomly 
selected H&E stained slides containing one or more prostate biopsy cores were digitized and 
reviewed using Aperio ImageScope Viewer Software by two pathologists. In biopsy cores with 
both tumor and benign tissue, only benign tissue was reviewed. The pathologists recorded the 
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presence of any inflammatory cells in each biopsy core and the approximate percentage of total 
biopsy core area with inflammatory cell involvement. 
To assess the abundance of specific immune cell types, an average of 2 (range: 1-3) 
randomly selected unstained slides containing one or more biopsy cores were 
immunohistochemically (IHC) stained for 1) CD4 (CD4+ T cells), 2) CD8 (CD8+ T cells), 3) 
FoxP3 (Tregs), 4) CD68+ cells (macrophages), and 5) c-KIT (mast cells).  These immune cell 
types were chosen by immunologists and pathologists as cell types that were expected to be 
observed within the prostate, based on prior studies from tissue collected for indication. Each 
slide was visually reviewed and scored by a pathologist on a scale of 0-4, with 0 indicating no 
cells identified and 4 indicating an extensive number of cells. 
 
Statistical Analysis 
Characteristics of current users and non-users of aspirin at trial entry were described 
using medians for continuous variables and proportions for categorical variables. In univariable 
analyses, proportions, chi-square tests, and Cochran-Armitage trend tests were used to 
compare each outcome of interest by aspirin use. These outcomes included 1) the presence of 
intraprostatic inflammation, defined as having at least one biopsy core with inflammation (yes, 
no), 2) the extent of intraprostatic inflammation, defined as the percentage of biopsy cores with 
inflammation (categorized as 0%, >0% but <100%, and 100%), and 3) the abundance of 
markers of each immune cell type. Because multiple slides per person were reviewed, and 
because each slide had varying numbers of biopsy cores, a weighted average score for each 
immune cell marker was calculated based on the number of cores per scored slide. Using this 
weighted score, the abundance of each immune cell marker was categorized as low (less than 
the median, i.e. <1), medium (1), or high (>1).   
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Multivariable regression models were used to examine the association between aspirin 
use and inflammation/immune cells after adjusting for potential confounders. The presence of 
inflammation was modeled using logistic regression, and the extent of inflammation and 
abundance of immune cell markers were modeled using nominal polytomous logistic regression. 
Ordinal logistic regression was also attempted, but the proportional odds assumption did not 
hold. Multivariable models were adjusted for age (continuous), race (white, non-white), BMI 
(continuous), cigarette smoking status (current, former, never), physical activity (sedentary, 
light, moderate, active), education (college, no college), and diabetes (yes, no).  
As a sensitivity analysis, univariable analyses were repeated, restricted to the LUTS 
controls, including men with IPSS<8 at baseline and at year 7, and men with IPSS<8 at baseline 
and baseline to year 7 slope <25th percentile (N=86). Analyses were also repeated after 
restricting to men who were not diagnosed with prostate cancer on the end-of-study biopsy 
(N=295), and men with a PSA <4 ng/mL immediately prior to the end-of-study biopsy (N=317). 
Men with a PSA ≥4 ng/mL could have been included in the primary analysis if they had a prior 
negative biopsy during trial follow-up, and were consequently not clinically indicated for biopsy 
at the end of the trial despite elevated PSA. These sensitivity analyses were conducted to 
ensure that the case-control sampling procedure for LUTS, the inclusion of men with prostate 
cancer, and the inclusion of who may have been clinically indicated for biopsy under stricter 
protocols did not meaningfully alter the results. All statistical tests were two-sided, and p-values 
<0.05 were considered statistically significant. Analyses were conducted in SAS version 9.4. 
 
Results 
 There were 357 men from the placebo arm of PCPT included in this analysis. The 
median age at the end-of-study biopsy was 70 years old, and the median PSA was 1.50 ng/mL. 
Of these men, 155 (43%) reported aspirin use at trial entry. Other baseline characteristics of the 
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study population, by aspirin use at trial entry, are displayed in Table 4-1. Of note, aspirin users 
were less likely than non-users to have a college education (47% vs. 57%), less likely to be 
never smokers (25% vs. 40%), and more likely to be very active (16% vs 9%). At the end-of-
study biopsy, 21% of aspirin users and 15% of non-users were diagnosed with prostate cancer. 
 A median of 4 biopsy cores per person were assessed for inflammation (range: 1-11). 
The prevalence of having at least one biopsy core with inflammation was similar among aspirin 
users and non-users (66% vs. 67% for aspirin users and non-users, respectively, Table 4-2). 
However, the extent of inflammation appeared lower among users. Specifically, only 4% of 
aspirin users compared to 10% of non-users had inflammation in all biopsy cores examined, 
(Table 4-2). Consistent with these univariable results, aspirin use was not associated with the 
presence of inflammation (OR: 0.91, 95% CI: 0.57-1.47), but was inversely associated with odds 
of having all versus no biopsy cores with inflammation (OR: 0.31, 95% CI: 0.11-0.91, Table 4-3) 
after multivariable adjustment. 
 There were 321, 326, 315, 325, and 297 men with data on abundance of CD4, CD8, 
FoxP3, CD68, and c-Kit positive cells, respectively. A median of 4 biopsy cores per person 
(range: 0.5-14) were stained for CD4, CD8, FoxP3, and CD68 cells, and a median of 2.5 cores 
per person (range: 0.5-10) were stained for c-Kit cells. For all markers, the median and mode 
weighted average score were 1. In univariable analyses, aspirin users appeared more likely to 
have a low abundance (i.e. scores <1) of CD4, CD8, FoxP3, and CD68 cells, and high 
abundance (i.e. scores >1) of c-KIT cells compared to non-users (Table 4-2, Figure 4-1). The 
difference between users and non-users in FoxP3 abundance was statistically significant. 
Compared with medium abundance, aspirin use remained positively associated with odds of low 
FoxP3 abundance (OR: 3.39, 95% CI: 1.06-10.91) and inversely associated with odds of high 
FoxP3 abundance (OR: 0.62, 95% CI: 0.35-1.08, Table 4-4) after multivariable adjustment.  
Similar patterns were observed for all outcomes in sensitivity analyses restricted to 
LUTS controls (Supplemental Table 4-1), men without prostate cancer (Supplemental Table 
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This study examined associations between aspirin use and the overall presence and 
extent of inflammation, as well as markers of specific immune cells, in benign prostate tissue. 
We found that the proportion of men with at least one biopsy core with inflammation was similar 
among aspirin users and non-users, but that aspirin users were less likely to have inflammation 
in all biopsy cores examined. The abundance of certain immune cell markers also differed by 
level of aspirin use. Specifically, FoxP3, a marker of Tregs, appeared less abundant in benign 
prostate tissue of aspirin users as compared to non-users. 
To our knowledge, this is the first study to examine the relationship between aspirin use 
and inflammation in the prostate of men without biopsy indication. Other studies have examined 
aspirin use in relation to circulating markers of inflammation (54-64), but circulating markers are 
not necessarily indicative of inflammation within the prostate, where inflammation pertaining to 
prostate cancer is most etiologically relevant. The magnitude of the association was modest, 
with 4% of aspirin users vs. 10% of non-users exhibiting inflammation in all biopsy cores 
examined, and the same percentage of users and non-users having 0% of cores with 
inflammation. Whether these differences are clinically important is unknown, but this study 
provides early evidence that anti-inflammatory effects of aspirin may be observable in the 
prostate. 
 We also observed a lower abundance of Tregs in aspirin users as compared to non-
users. This finding is plausible given that aspirin, via inhibition of COX-2, inhibits synthesis of 
prostaglandin E2, which has been shown to promote development of Tregs (105). Tregs 
downregulate the immune system and may block T cells from mounting an effective anti-tumor 
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response (70, 106, 107). In accordance with this proposed pro-tumorigenic role, studies have 
found Tregs to be more prevalent in tumor vs. benign prostate tissue from the same patients, 
and in peripheral blood of prostate cancer vs. non-prostate cancer donors (108). Greater 
numbers of epithelial Tregs have also been positively associated with Gleason sum and 
pathologic stage (109). On the other hand, Tregs could also reduce cancer-promoting 
inflammation, which could inhibit cancer development (110). Thus, while our study suggests that 
aspirin may lower the number of Tregs in the prostate, additional studies of Tregs and prostate 
cancer incidence and progression are needed to better understand the implications of this 
finding. 
Limitations of this study include the small sample size and cross-sectional study design. 
Aspirin use was ascertained at trial entry, seven years prior to the end-of-study biopsy, but 
whether inflammation was already present at baseline was unknown. Information was not 
available on history of aspirin use prior to trial enrollment, on aspirin use initiated during the trial 
period, or on whether men stopped taking aspirin before the end-of-study biopsy, and so some 
misclassification of exposure may have occurred. Furthermore, data were not collected on 
aspirin dose, frequency of use, or duration of use, and we were thus unable to examine how 
these variations in aspirin use influenced inflammation or immune cell markers. Finally, for each 
immune cell marker, IHC was unsuccessful for some individuals (range: 9-17%) due to 
unavailability of slides, insufficient tissue on slides, or problems with staining. As a result, the 
sample size varied across analyses of each marker. 
This study also has several notable strengths. There was detailed assessment of 
multiple outcomes, including both the presence and extent of inflammation and markers of 
innate and adaptive immune cells. Such detailed assessment allowed us to not only quantify the 
extent of inflammation within prostate tissue, but to understand the specific immune cells that 
might be modulating the inflammatory response. IHC staining was performed by a single 
laboratory using validated, standardized protocols, thereby minimizing opportunities for errors. 
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Importantly, inflammation and immune cell markers were measured in prostate tissue collected 
without indication for biopsy, thus avoiding the selection bias that arises when only men with 
elevated PSA and suspected prostate cancer are included. 
This study provides direct population-based evidence that aspirin use may influence 
inflammation and the immune cell milieu within the prostate of men without indication for biopsy. 
Further research is needed to confirm these observational findings, but results from this study 
support our hypothesis that intraprostatic inflammation may mediate the relationship between 
regular aspirin use and prostate cancer risk. 
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Chapter 4 Tables 
 
Table 4-1. Characteristics* of a subset** of men from the placebo arm of PCPT, by aspirin 
use at trial entry 
 
 No Aspirin Use Aspirin Use 
N 202 155 
Age at biopsy, median 69 70 
Race, %   
White 96 96 
Non-white 4 4 
College education, % 57 47 
Diabetes, % 5 6 
BMI (kg/m2), median  26.8 27.4 
Smoking status, %   
Current 8 7 
Former 51 68 
Never 40 25 
Pack-years of smoking, median*  21.3 23.9 
Physical activity, %   
Sedentary 23 22 
Light 13 16 
Moderate 54 46 
Very active 9 16 
Missing 1 0 
Daily intake, median   
Energy (kcal) 2062 2016 
Vegetables (servings/day) 1.9 2.0 
Total fat (g) 71.9 69.1 
Polyunsaturated fatty acids (g) 14.6 14.7 
Total protein (g) 83.7 84.4 
Red meat (servings/week) 3.5 3.9 
Alcoholic beverages (drinks/day) 0.3 0.2 
PSA at biopsy (ng/mL), median 1.6 1.4 
Prostate cancer diagnosis, % 15 21 
BMI, body mass index; PSA, prostate-specific antigen 
*All variables were assessed at trial entry, with the exception of age, PSA, and prostate cancer diagnosis 
**From a case-control study of LUTS nested in the placebo arm of PCPT. The men did not have a clinical indication 




Table 4-2. Presence and extent of intraprostatic inflammation* and abundance of immune 
cell markers** by aspirin use at baseline, in a subset*** of men from the placebo arm of 
PCPT 
 
 No Aspirin Use Aspirin Use p-value**** 
≥1 core with inflammation, % 67 66 0.8 
Percent of cores with 
inflammation, % 
   
None 34 34 0.3 
Some 55 62  
All 10 4  
CD4, %    
Low 16 21 0.2 
Medium 42 42  
High 42 37  
CD8, %    
Low 9 12 0.3 
Medium 69 70  
High 22 18  
FoxP3, %    
Low 3 8 0.01 
Medium 66 70  
High 31 21  
CD68, %    
Low 13 15 0.2 
Medium 75 76  
High 13 9  
c-KIT, %    
Low 11 7 0.1 
Medium 74 72  
High 15 21  
*Extent of inflammation categorized as: none: 0% of cores with inflammation, some: >0% but <100% of cores with 
inflammation, all: 100% of cores with inflammation 
**Abundance was scored on a scale of 0-4. When multiple slides per individual were scored, a weighted average was 
calculated using the number of cores per slide. Abundance was categorized based on the median value of 1 (low: <1, 
medium: 1, high: >1) 
***From a case-control study of LUTS nested in the placebo arm of PCPT. The men did not have a clinical indication 
for biopsy. 







Table 4-3. Associations between aspirin use and the presence and extent of 
intraprostatic inflammation in a subset* of men from the placebo arm of PCPT 
 
 At least one core with inflammation 
 No Yes  
# aspirin users / non-users 53 / 67 102 / 135  
Model 1 OR (95% CI) Ref 0.96 (0.61-1.49)  
Model 2 OR (95% CI) Ref 0.87 (0.55-1.37)  
Model 3 OR (95% CI) Ref 0.91 (0.57-1.47)  
 Percent of cores with inflammation 
 None Some All 
# aspirin users / non-users 53 / 69 96 / 112 6 / 21 
Model 1 OR (95% CI) Ref 1.12 (0.71-1.75) 0.37 (0.14-0.99) 
Model 2 OR (95% CI) Ref 1.02 (0.64-1.63) 0.31 (0.11-0.84) 
Model 3 OR (95% CI) Ref 1.04 (0.64-1.69) 0.31 (0.11-0.91) 
*From a case-control study of LUTS nested in the placebo arm of PCPT. The men did not have a clinical indication for 
biopsy. 
Model 1: unadjusted 
Model 2: adjusted for age and race 
Model 3: adjusted for age (continuous), race (white, non-white), BMI (continuous), smoking status (current, former, 
never), physical activity (sedentary, light, moderate, active), education (college, no college), diabetes (yes, no) 







Table 4-4. Associations between aspirin use at baseline and the abundance of immune 
cell markers* in a subset** of men from the placebo arm of PCPT 
 
 CD4 (n=321) 
 Low Medium High 
# aspirin users / non-users 31 / 28 61 / 73 55 / 73 
Model 1 OR (95% CI) 1.33 (0.72-2.45) Ref 0.90 (0.55-1.47) 
Model 2 OR (95% CI) 1.38 (0.74-2.56) Ref 0.87 (0.53-1.43) 
Model 3 OR (95% CI) 1.43 (0.75-2.74) Ref 0.90 (0.54-1.51) 
 CD8 (n=326) 
 Low Medium High 
# aspirin users / non-users 18 / 16 104 / 122 27 / 39 
Model 1 OR (95% CI) 1.32 (0.64-2.72) Ref 0.81 (0.47-1.42) 
Model 2 OR (95% CI) 1.34 (0.65-2.77) Ref 0.78 (0.44-1.36) 
Model 3 OR (95% CI) 1.18 (0.55-2.51) Ref 0.73 (0.41-1.31) 
 FoxP3 (n=315) 
 Low Medium High 
# aspirin users / non-users 12 / 5 100 / 115 30 / 53 
Model 1 OR (95% CI) 2.76 (0.94-8.10) Ref 0.65 (0.39-1.10) 
Model 2 OR (95% CI) 3.30 (1.10-9.89) Ref 0.60 (0.35-1.03) 
Model 3 OR (95% CI) 3.39 (1.06-10.91) Ref 0.62 (0.35-1.08) 
 CD68 (n=325) 
 Low Medium High 
# aspirin users / non-users 23 / 22 113 / 132 13 / 22 
Model 1 OR (95% CI) 1.22 (0.65-2.31) Ref 0.69 (0.33-1.43) 
Model 2 OR (95% CI) 1.16 (0.61-2.21) Ref 0.67 (0.32-1.39) 
Model 3 OR (95% CI) 1.05 (0.53-2.06) Ref 0.64 (0.30-1.38) 
 c-Kit (n=297) 
 Low Medium High 
# aspirin users / non-users 9 / 18 93 / 125 27 / 25 
Model 1 OR (95% CI) 0.67 (0.29-1.56) Ref 1.45 (0.79-2.66) 
Model 2 OR (95% CI) 0.63 (0.27-1.49) Ref 1.44 (0.78-2.66) 
Model 3 OR (95% CI) 0.51 (0.20-1.26) Ref 1.44 (0.76-2.71) 
*Abundance was scored on a scale of 0-4. When multiple slides per individual were scored, a weighted average was 
calculated using the number of cores per slide. Abundance was categorized based on the median value of 1 (low: <1, 
medium: 1, high: >1) 
**From a case-control study of LUTS nested in the placebo arm of the PCPT. The men did not have a clinical 
indication for biopsy. 
Model 1: unadjusted 
Model 2: adjusted for age and race 
Model 3: adjusted for age (continuous), race (white, black), BMI (continuous), smoking status (current, former, never), 
physical activity (sedentary, light, moderate, active), education (college, no college), diabetes (yes, no) 








Figure 4-1. Abundance of FoxP3 in aspirin users and non-users. As shown in the overlaid 
histograms above, the distribution of FoxP3 was similar overall across level of aspirin use. 
However, there was more weight in the lower end of the distribution for aspirin users, and more 





Appendix 4-1. Supplemental Tables 
 
Supplemental Table 4-1. Presence and extent of intraprostatic inflammation* and 
abundance of immune cell markers** by aspirin use at baseline, in a subset*** of men from 
the placebo arm of PCPT who did not have LUTS****, n=86 
 
 No Aspirin Use Aspirin Use p-value***** 
≥1 core with inflammation, % 67 63 0.8 
Percent of cores with 
inflammation, % 
   
None 33 37 0.2 
Some 56 63  
All 11 0  
CD4, %    
Low 11 20 0.4 
Medium 50 46  
High 39 34  
CD8, %    
Low 8 11 0.8 
Medium 77 73  
High 15 16  
FoxP3, %    
Low 3 9 0.2 
Medium 71 74  
High 26 17  
CD68, %    
Low 13 14 0.8 
Medium 77 78  
High 10 8  
c-KIT, %    
Low 11 3 0.1 
Medium 82 80  
High 8 17  
*Extent of inflammation categorized as: none: 0% of cores with inflammation, some: >0% but <100% of cores with 
inflammation, all: 100% of cores with inflammation 
** Abundance was scored on a scale of 0-4. When multiple slides per individual were scored, a weighted average was 
calculated using the number of cores per slide. Abundance was categorized based on the median value of 1 (low: <1, 
medium: 1, high: >1) 
***From a case-control study of LUTS nested in the placebo arm of the PCPT. The men did not have a clinical 
indication for biopsy. 
****LUTs controls included men with IPSS<8 at baseline and at year 7 (n=41) and men with IPSS<8 at baseline and 
baseline to year 7 slope <25th percentile (n=45) 




Supplemental Table 4-2. Presence and extent of intraprostatic inflammation* and 
abundance of immune cell markers** by aspirin use at baseline, in a subset*** of men from 
the placebo arm of PCPT without cancer detected at the end-of-study biopsy, n=295 
 
 No Aspirin Use Aspirin Use p-value**** 
≥1 core with inflammation, % 69 64 0.4 
Percent of cores with 
inflammation, % 
   
None 32 36 0.1 
Some 57 60  
All 11 4  
CD4, %    
Low 16 23 0.2 
Medium 43 40  
High 41 37  
CD8, %    
Low 7 12 0.3 
Medium 72 71  
High 20 18  
FoxP3, %    
Low 3 9 <0.01 
Medium 66 74  
High 31 18  
CD68, %    
Low 14 18 0.2 
Medium 76 74  
High 11 8  
c-KIT, %    
Low 11 8 0.3 
Medium 74 73  
High 15 19  
*Extent of inflammation categorized as: none: 0% of cores with inflammation, some: >0% but <100% of cores with 
inflammation, all: 100% of cores with inflammation 
**Abundance was scored on a scale of 0-4. When multiple slides per individual were scored, a weighted average was 
calculated using the number of cores per slide. Abundance was categorized based on the median value of 1 (low: <1, 
medium: 1, high: >1) 
***From a case-control study of LUTS nested in the placebo arm of the PCPT. The men did not have a clinical 
indication for biopsy. 
****p-value from the chi-square test (for dichotomous variables) or Cochran-Armitage trend test (for ordinal variables) 
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Supplemental Table 4-3. Presence and extent of intraprostatic inflammation* and 
abundance of immune cell markers** by aspirin use at baseline, in a subset*** of men 
from the placebo arm of PCPT without clinical indication for biopsy, n=317 
 
 No Aspirin Use Aspirin Use p-value**** 
≥1 core with inflammation, % 67 66 0.8 
Percent of cores with 
inflammation, % 
   
None 34 34 0.4 
Some 56 62  
All 10 4  
CD4, %    
Low 15 23 0.2 
Medium 46 41  
High 39 36  
CD8, %    
Low 9 13 0.3 
Medium 70 69  
High 22 19  
FoxP3, %    
Low 3 8 0.05 
Medium 69 72  
High 28 20  
CD68, %    
Low 12 16 0.3 
Medium 77 75  
High 11 9  
c-KIT, %    
Low 10 8 0.1 
Medium 77 72  
High 13 21  
*Extent of inflammation categorized as: none: 0% of cores with inflammation, some: >0% but <100% of cores with 
inflammation, all: 100% of cores with inflammation 
**Abundance was scored on a scale of 0-4. When multiple slides per individual were scored, a weighted average was 
calculated using the number of cores per slide. Abundance was categorized based on the median value of 1 (low: <1, 
medium: 1, high: >1) 
***From a case-control study of LUTS nested in the placebo arm of the PCPT. The men did not have a clinical 
indication for biopsy. 











Key findings, implications, and future directions 
The purpose of this dissertation was to address research gaps pertaining to the role of 
aspirin and non-aspirin nonsteroidal anti-inflammatory drugs (NA-NSAIDs) in prostate cancer 
prevention and control. Specifically, this dissertation aimed to determine whether aspirin or NA-
NSAID use might protect against prostate cancer development, and particularly development of 
lethal prostate cancer. This dissertation also investigated whether NSAID use among men 
already diagnosed with prostate cancer might reduce the risk of prostate cancer recurrence or 
case-fatality. We hypothesized that chronic inflammation within the prostate might mediate 
these effects, and tested the biological plausibility of this mechanism by comparing intraprostatic 
inflammation and markers of immune cells in aspirin users and non-users. The overarching goal 
of these studies was to inform strategies for the primary and tertiary prevention of lethal prostate 
cancer.   
 
Aspirin and NA-NSAID use and prostate cancer incidence and mortality 
The first aim investigated the relationship between aspirin and NA-NSAID use and 
prostate cancer incidence, including incidence of lethal disease, and prostate cancer mortality in 
the Atherosclerosis Risk in Communities (ARIC) study. While NA-NSAID use was not 
associated with total, lethal, or fatal prostate cancer, aspirin use was inversely associated with 
both lethal and fatal prostate cancer. These results are consistent with two previous cohort 
studies, which also reported inverse associations between aspirin use and lethal prostate (43, 
44). In ARIC, the magnitude of the associations was striking, with aspirin users exhibiting a 42% 
(95% confidence interval [CI]: 5-65%) lower risk of lethal prostate cancer relative to non-users, 
even after adjusting for potential confounders. Importantly, the magnitude of the association was 




cancer regardless of race and the underlying sociocultural and genetic factors that contribute to 
current prostate cancer racial disparities. 
While these results are promising, the number of events in our analysis was small, and 
larger studies are needed to confirm our results and produce more precise point estimates. 
Given the observational nature of our study and similar studies, replication of these findings 
across multiple study populations is also needed to build support for a causal relationship.  With 
additional research, increasingly specific questions should be addressed, such as how aspirin 
dose, frequency of use, duration of use, and age at initiation of use affect risk of lethal prostate 
cancer. Our study suggests that aspirin may only be protective against lethal prostate cancer if 
used regularly for cardiovascular disease (CVD) prevention (i.e. daily use of low-dose aspirin), 
but this finding is preliminary and requires further investigation. Answering these questions may 
require pooling of data from existing observational studies or randomized clinical trials (RCTs) of 
aspirin and other disease outcomes, if sufficient data are available, or creation of entirely new, 
large-scale cancer epidemiology cohorts, which could take several decades. Answering these 
finer questions is necessary, however, before results can be translated into clinical practice. 
Additional research could also help to determine precisely who might benefit most from 
aspirin chemoprevention. For example, genetic factors that influence aspirin absorption, 
distribution, metabolism, and excretion might make individuals more likely to benefit from aspirin 
use, or more susceptible to its harms (81). For colorectal cancer (CRC), certain single 
nucleotide polymorphisms (SNPs) have been found to modify associations between NSAID use 
and CRC risk (111); these SNPs might modify the association between aspirin use and lethal 
prostate cancer as well.  Aspirin might also be more effective among individuals with other lethal 
prostate cancer risk factors. Aspirin use has been shown to lessen the effect of obesity on CRC 
among individuals with Lynch syndrome (112) and to reduce risk of gastric cancer among 
individuals treated for Helicobacter pylori infection (113). For lethal prostate cancer, aspirin 




hypothesized to contribute to lethal prostate cancer, in part, by generating chronic inflammatory 
states. Given the known harms of regular aspirin use, including risk of gastrointestinal bleeding 
and hemorrhagic stroke, identifying finer subgroups of men most likely to benefit would help to 
better tailor recommendations and minimize harms. 
If additional studies confirm the inverse association between aspirin use and lethal 
prostate cancer, these findings may eventually help inform guidelines for regular aspirin use. In 
the general population, regular aspirin use is currently recommended for certain individuals at 
increased risk of CVD (39). Specifically, in 2016, the United States Preventive Services Task 
Force (USPSTF) recommended low-dose aspirin (grade: B) for individuals ages 50-59 with a 
10% or greater 10-year risk of CVD, a life expectancy of at least 10 years, no increased risk of 
bleeding, and willingness to take aspirin daily for at least 10 years (39). These guidelines 
considered benefits of aspirin pertaining to CVD and CRC, but not other cancer types due to 
limitations in the evidence (114). Eventually, if studies consistently observe inverse associations 
between aspirin use and lethal prostate cancer, and if these findings are incorporated into risk-
benefit calculations, the benefits of regular aspirin use may begin to outweigh the harms for 
additional segments of the general population. Moreover, even if the risk-benefit balance for the 
general population is not meaningfully altered, the balance may change for certain high-risk 
individuals. Ideally, any new or updated guidelines would be based on evidence from 
randomized controlled trials (RCTs), but given issues with feasibility and lack of clinical 
equipoise, an RCT of aspirin for primary prevention of lethal prostate cancer is unlikely, and 
well-designed observational studies are needed to develop this burgeoning evidence base. 
 
Aspirin and NA-NSAID use and prostate cancer recurrence and case-fatality 
The second aim of this dissertation investigated the relationship between aspirin and 




Among men diagnosed with prostate cancer in the ARIC study, current aspirin use at the visit 
prior to diagnosis was inversely associated with risk of dying of prostate cancer (HR: 0.45, 95% 
CI: 0.22-0.94). In contrast, in the Johns Hopkins Hospital (JHH) study, aspirin use pre- and post-
surgery were not inversely associated with prostate cancer recurrence, and may have been 
associated with an increased risk. Findings for NA-NSAID use were null in both study 
populations. Other studies that have examined pre- or post-diagnostic aspirin and NA-NSAID 
use and prostate cancer case-fatality have also reported mixed results (44, 46-51, 53, 78, 79, 
115). 
There are several possible explanations for these seemingly conflicting results. First, the 
ARIC and JHH studies included different measures of aspirin use. In ARIC, the exposure of 
interest was current aspirin use at the study visit prior to prostate cancer diagnosis (median = 
5.7 years prior to diagnosis). In JHH, aspirin use was assessed at the time of the preoperative 
consultation (immediately after diagnosis), pre-surgery (which may have been before or after 
diagnosis), and post-surgery. It is possible that aspirin may only be protective at certain stages 
in the natural history of prostate cancer, and that measurement of aspirin in ARIC overlapped 
the etiologically relevant time window of exposure while measurement of aspirin in JHH did not. 
The two studies also examined different outcomes. In ARIC, the primary outcome was prostate 
cancer case-fatality, while in JHH, the primary outcome was prostate cancer recurrence, which 
was defined as a composite outcome but included mostly biochemical recurrences (62%) and 
local recurrences (8%). Biochemical recurrence is an early indicator of poor outcomes, but not 
all biochemically recurrent prostate cancers become metastatic and/or fatal. The inverse 
association in ARIC, contrasted with the null associations in JHH, could thus be explained if 
aspirin reduces risk of distant metastasis but not local recurrence or regional spread.    
There were also key differences in the study populations. In ARIC, the study population 
skewed older (mean age at diagnosis = 69) and included white and black men diagnosed with 




all were good surgical candidates, i.e. younger (mean age at diagnosis = 56) with clinically 
localized disease at diagnosis. Differences in results could thus be driven by potential 
differences in the effect of aspirin by age, race, or disease stage at diagnosis. The two study 
populations also received different prostate cancer treatments. In ARIC, men could have 
received any type of treatment from any healthcare provider. Because treatment is associated 
with survival, at least for advanced prostate cancer, and because factors such as 
socioeconomic status may be associated with both aspirin use and access to of or quality of 
treatment, the association between aspirin use and case-fatality may have been confounded in 
ARIC. In contrast, in the JHH study, all men underwent surgery by the same surgeon at the 
same hospital, and so while generalizability was more limited, confounding by access to care 
was not a concern. Instead, the null findings in this study could indicate that aspirin does not 
confer any added benefit for men with localized prostate cancer treated surgically, who already 
have a good prognosis. 
Due to these lingering uncertainties, additional research is still needed to elucidate 
whether aspirin used pre-diagnostically or post-diagnostically may reduce risk of poor prostate 
cancer outcomes. Studies of pre-diagnostic aspirin use are needed to replicate our findings from 
ARIC and determine whether aspirin may act early in the disease pathogenesis to prevent 
progression to more lethal disease. Studies of post-diagnostic aspirin use are needed to confirm 
our findings from JHH and discern whether recommending aspirin to men already diagnosed 
with prostate cancer may improve prostate cancer outcomes, make outcomes worse, or have 
no impact. In comparison to studies of aspirin use for primary prevention of lethal prostate 
cancer, studies of post-diagnostic aspirin use and prostate cancer recurrence are more 
amenable to an RCT, given the uncertain risk-benefit balance for this population, the higher rate 
of recurrence events, and the shorter duration of follow-up needed to observe these events.  
Enrollment for one such trial, Add-Aspirin, is currently underway (116). For this trial, four 




or prostate cancer are being randomized in a 1:1:1 ratio to 100 mg aspirin, 300 mg aspirin, or 
placebo, to be taken daily for at least five years. The prostate cancer arm of this trial includes 
men treated with surgery or radiotherapy for early-stage prostate cancer in the United Kingdom 
and India, and will examine biochemical recurrence-free survival as its primary endpoint. The 
recruitment goal for the prostate cancer arm is 2,120 participants; as of February 2018, 865 
participants had been registered and 696 had been randomized (117). Though it will be several 
years before results are released, and though this trial will not be able to speak to the effects of 
aspirin on advanced-stage disease, or on outcomes worse than biochemical recurrence, this 
trial may at least provide more definitive answers as to whether post-diagnostic aspirin use 
reduces risk of biochemical recurrence for men with early-stage prostate cancer. For now, 
however, there is insufficient evidence to recommend aspirin or NA-NSAIDs for the tertiary 
prevention of lethal prostate cancer. 
 
Aspirin use and inflammation and immune cell profiling in benign prostate tissue 
 For the third aim of this dissertation, associations between aspirin use and the presence 
and extent of inflammation in benign prostate tissue, as well as abundance of specific immune 
cells, were assessed in a subset of men from the placebo arm of the Prostate Cancer 
Prevention Trial (PCPT). Aspirin use at trial entry was not associated with the presence of any 
inflammation in benign tissue from the end-of-study biopsy, but the extent of inflammation was 
moderately lower in aspirin users as compared to non-users. Aspirin users also had moderately 
lower scores for FoxP3 cells, indicating lower abundance of Tregs. Importantly, these 
associations were observed among men without a clinical indication for prostate biopsy, and in 
sensitivity analyses, among men without prostate cancer, with low PSA, and with low or very 
low LUTS, suggesting that the presence of preexisting prostate conditions was not biasing 




cell milieu within the prostate, which could be a possible mechanism linking aspirin use to 
prostate cancer development and progression.  
 This research is ongoing and will be updated as additional data become available. 
Specifically, we will soon be able to incorporate data on aspirin use initiated during the trial, 
which will allow us to better classify individuals as aspirin users or non-users and examine the 
impact of duration of use during the trial period. Information on use of statins during the trial is 
also forthcoming. Statins are commonly used concurrently with aspirin, including in PCPT (118), 
and may also alter the extent of inflammation and abundance of immune cell types within the 
prostate, and so future analyses will adjust for use of statins to reduce potential confounding. 
 Ideally, our findings will also be replicated in additional study populations. To obtain 
unbiased estimates, these additional studies will need access to prostate tissue collected 
without clinical indication, since indications for prostate tissue removal (i.e. elevated PSA, 
benign prostatic hyperplasia, prostate cancer) are associated with intraprostatic inflammation 
(65, 102, 103) and also possibly aspirin use. Replication in observational studies may thus not 
be possible, as prostate tissue is not typically collected without clinical indication. A small trial 
could be designed to assess the effect of randomization to aspirin on inflammation and immune 
cell markers, assuming men would agree to undergo a not-for-cause biopsy. Such a trial would 
face several barriers, including high costs and challenges with recruitment, but would help to 
bolster support for a causal relationship between aspirin use and intraprostatic inflammation. A 
much larger trial could also continue to follow men for incident total or lethal prostate cancer so 
that a formal mediation analysis could be conducted. However, this trial would need to biopsy 
participants at baseline to exclude men with prevalent prostate cancer and again after aspirin 
treatment, to follow participants for several years to observe incident events. This trial would 
also need to enroll huge numbers of participants to be adequately powered, and as a result, 




 Understanding the relationship between aspirin use and intraprostatic inflammation and 
immune cells might also help inform interventions at other stages of the prostate cancer care 
continuum. For example, for treatment of advanced prostate cancer, there is currently great 
interest and promise in cancer immunotherapies, include vaccines such as Provenge and 
checkpoint inhibitors. The response rate for immunotherapies has been low for many cancer 
types, and particularly for prostate cancer. However, there is pre-clinical evidence from 
melanoma mouse models that aspirin might enhance the efficacy of checkpoint inhibitors (119). 
Pre-clinical work also suggests that aspirin may act synergistically with other therapies for 
advanced cancer, such as kinase inhibitors used to treat RAS-mutant cancers (120). These 
findings are not directly applicable to prostate cancer, since prostate cancers respond poorly to 
checkpoint inhibitors and are rarely RAS-positive. However, while still preliminary, these studies 
suggest that there may be a role for aspirin in improving certain advanced cancer treatments. 
For prostate cancer, elucidating how aspirin impacts immune cells in the prostate could 
eventually help to propel similar studies forward.   
 
Conclusion 
This dissertation provides evidence that aspirin but not NA-NSAID use may reduce risk 
of lethal prostate cancer in both black and white men. Whether aspirin also reduces risk of 
disease recurrence and/or progression among men diagnosed with prostate cancer remains 
unclear, but this question warrants further investigation given the strong inverse association 
between pre-diagnostic aspirin use and case-fatality observed in the ARIC study. Biological 
plausibility of a relationship between aspirin use and lethal prostate cancer is supported by 
observed differences in the extent of inflammation and abundance of specific immune cells in 
benign prostate tissue of aspirin users and non-users. Collectively, these studies suggest that 
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